CN103987708B - 4-羟基-1,2,3,4-四氢萘-1-基脲的衍生物及其在呼吸道疾病治疗中的用途 - Google Patents
4-羟基-1,2,3,4-四氢萘-1-基脲的衍生物及其在呼吸道疾病治疗中的用途 Download PDFInfo
- Publication number
- CN103987708B CN103987708B CN201180075375.9A CN201180075375A CN103987708B CN 103987708 B CN103987708 B CN 103987708B CN 201180075375 A CN201180075375 A CN 201180075375A CN 103987708 B CN103987708 B CN 103987708B
- Authority
- CN
- China
- Prior art keywords
- base
- pyridine
- triazol
- tert
- butyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000004202 carbamide Substances 0.000 title claims description 111
- 208000023504 respiratory system disease Diseases 0.000 title description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title description 3
- 241001597008 Nomeidae Species 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 140
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 27
- 201000010099 disease Diseases 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 144
- 229910052760 oxygen Inorganic materials 0.000 claims description 128
- 239000001301 oxygen Substances 0.000 claims description 127
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 120
- 239000000203 mixture Substances 0.000 claims description 87
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims description 18
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 16
- 208000006673 asthma Diseases 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 10
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 8
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 8
- 210000004072 lung Anatomy 0.000 claims description 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 5
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 5
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 5
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000000068 chlorophenyl group Chemical group 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 3
- 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 claims description 2
- 230000036428 airway hyperreactivity Effects 0.000 claims description 2
- 230000008901 benefit Effects 0.000 claims description 2
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 claims description 2
- 230000006866 deterioration Effects 0.000 claims description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract description 15
- 239000003112 inhibitor Substances 0.000 abstract description 9
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 5
- 208000018569 Respiratory Tract disease Diseases 0.000 abstract description 3
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 abstract 1
- 239000002585 base Substances 0.000 description 245
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 147
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 128
- 239000000243 solution Substances 0.000 description 126
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 87
- 238000000034 method Methods 0.000 description 66
- 235000019439 ethyl acetate Nutrition 0.000 description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 54
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 44
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 43
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 41
- 238000005160 1H NMR spectroscopy Methods 0.000 description 33
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 32
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 32
- 239000007787 solid Substances 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 26
- 239000000284 extract Substances 0.000 description 24
- 239000000376 reactant Substances 0.000 description 23
- 238000000746 purification Methods 0.000 description 21
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 20
- 238000001704 evaporation Methods 0.000 description 20
- 235000019253 formic acid Nutrition 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 19
- 230000008020 evaporation Effects 0.000 description 19
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- -1 N-piperazinyl Chemical group 0.000 description 17
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 150000001412 amines Chemical class 0.000 description 16
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 16
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 15
- 239000012044 organic layer Substances 0.000 description 15
- 229910052938 sodium sulfate Inorganic materials 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 239000007832 Na2SO4 Substances 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 238000001816 cooling Methods 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 13
- 239000012267 brine Substances 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 239000003480 eluent Substances 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 229910052786 argon Inorganic materials 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- 102100040247 Tumor necrosis factor Human genes 0.000 description 8
- 239000000443 aerosol Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 235000019580 granularity Nutrition 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- 235000008504 concentrate Nutrition 0.000 description 7
- 239000006260 foam Substances 0.000 description 7
- 239000002480 mineral oil Substances 0.000 description 7
- 235000010446 mineral oil Nutrition 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 239000012312 sodium hydride Substances 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- 108090001007 Interleukin-8 Proteins 0.000 description 6
- 102000004890 Interleukin-8 Human genes 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 208000027866 inflammatory disease Diseases 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 229960000278 theophylline Drugs 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 102000000589 Interleukin-1 Human genes 0.000 description 5
- 108010002352 Interleukin-1 Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 150000001450 anions Chemical class 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 5
- 239000003380 propellant Substances 0.000 description 5
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 239000012826 P38 inhibitor Substances 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229960003728 ciclesonide Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229960000289 fluticasone propionate Drugs 0.000 description 4
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 4
- 229960002848 formoterol Drugs 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229960002052 salbutamol Drugs 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 3
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 206010014561 Emphysema Diseases 0.000 description 3
- 208000035126 Facies Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
- 239000000048 adrenergic agonist Substances 0.000 description 3
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 230000005587 bubbling Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 150000004675 formic acid derivatives Chemical class 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- VHHHONWQHHHLTI-UHFFFAOYSA-N hexachloroethane Chemical compound ClC(Cl)(Cl)C(Cl)(Cl)Cl VHHHONWQHHHLTI-UHFFFAOYSA-N 0.000 description 3
- 229960004078 indacaterol Drugs 0.000 description 3
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- BMKINZUHKYLSKI-DQEYMECFSA-N n-[2-hydroxy-5-[(1r)-1-hydroxy-2-[2-[4-[[(2r)-2-hydroxy-2-phenylethyl]amino]phenyl]ethylamino]ethyl]phenyl]formamide Chemical compound C1([C@@H](O)CNC2=CC=C(C=C2)CCNC[C@H](O)C=2C=C(NC=O)C(O)=CC=2)=CC=CC=C1 BMKINZUHKYLSKI-DQEYMECFSA-N 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 3
- 230000000414 obstructive effect Effects 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000779 smoke Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- HXRVAPHVNZCFJM-UHFFFAOYSA-N (3-fluoropyridin-2-yl)hydrazine Chemical compound NNC1=NC=CC=C1F HXRVAPHVNZCFJM-UHFFFAOYSA-N 0.000 description 2
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
- KTOOMIYOUDGYCE-UHFFFAOYSA-N C1=CC=CC=C1.C(C)(=O)OIOC(C)=O Chemical compound C1=CC=CC=C1.C(C)(=O)OIOC(C)=O KTOOMIYOUDGYCE-UHFFFAOYSA-N 0.000 description 2
- 229940124003 CRTH2 antagonist Drugs 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- FCEZUBCYGHDJAC-UHFFFAOYSA-N N1=CC=C(C=C1)OF Chemical compound N1=CC=C(C=C1)OF FCEZUBCYGHDJAC-UHFFFAOYSA-N 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
- YYAZJTUGSQOFHG-IAVNQIGZSA-N [(6s,8s,10s,11s,13s,14s,16r,17r)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate;2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]eth Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)C1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O YYAZJTUGSQOFHG-IAVNQIGZSA-N 0.000 description 2
- URWYQGVSPQJGGB-DHUJRADRSA-N [1-[3-[2-chloro-4-[[[(2r)-2-hydroxy-2-(8-hydroxy-2-oxo-1h-quinolin-5-yl)ethyl]amino]methyl]-5-methoxyanilino]-3-oxopropyl]piperidin-4-yl] n-(2-phenylphenyl)carbamate Chemical compound ClC=1C=C(CNC[C@H](O)C=2C=3C=CC(=O)NC=3C(O)=CC=2)C(OC)=CC=1NC(=O)CCN(CC1)CCC1OC(=O)NC1=CC=CC=C1C1=CC=CC=C1 URWYQGVSPQJGGB-DHUJRADRSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- ASMXXROZKSBQIH-VITNCHFBSA-N aclidinium Chemical compound C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1 ASMXXROZKSBQIH-VITNCHFBSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229940092705 beclomethasone Drugs 0.000 description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000009267 bronchiectasis Diseases 0.000 description 2
- 229960004436 budesonide Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- 239000011928 denatured alcohol Substances 0.000 description 2
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002081 enamines Chemical class 0.000 description 2
- 210000003725 endotheliocyte Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940071648 metered dose inhaler Drugs 0.000 description 2
- 239000004531 microgranule Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 229940066491 mucolytics Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- RCIGDGBXEMECGY-UHFFFAOYSA-N pyridin-3-ylhydrazine Chemical compound NNC1=CC=CN=C1 RCIGDGBXEMECGY-UHFFFAOYSA-N 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229910052707 ruthenium Inorganic materials 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- NTNKNFHIAFDCSJ-UHFFFAOYSA-N (2-nitrophenyl) thiohypochlorite Chemical compound [O-][N+](=O)C1=CC=CC=C1SCl NTNKNFHIAFDCSJ-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- ZEYYDOLCHFETHQ-JOCHJYFZSA-N (2r)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid Chemical compound C1([C@@H](C(=O)O)C=2C=CC(OCC=3N=C4C=CC=CC4=CC=3)=CC=2)CCCC1 ZEYYDOLCHFETHQ-JOCHJYFZSA-N 0.000 description 1
- LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 description 1
- SPFPGSYLNIIQMG-UHFFFAOYSA-N (carboxyamino)carbamic acid Chemical compound OC(=O)NNC(O)=O SPFPGSYLNIIQMG-UHFFFAOYSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- PEPITGGBNOELSK-UHFFFAOYSA-N 2-(2-hydroxyethylsulfanyl)benzaldehyde Chemical compound OCCSC1=CC=CC=C1C=O PEPITGGBNOELSK-UHFFFAOYSA-N 0.000 description 1
- YSIHYROEMJSOAS-UHFFFAOYSA-N 2-(5-amino-6-oxo-2-phenylpyrimidin-1-yl)-n-[1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-3-methyl-1-oxobutan-2-yl]acetamide Chemical compound N=1N=C(C(C)(C)C)OC=1C(=O)C(C(C)C)NC(=O)CN(C(C(N)=CN=1)=O)C=1C1=CC=CC=C1 YSIHYROEMJSOAS-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- JWYIGNODXSRKGP-UHFFFAOYSA-N 2-[4-acetamido-3-(4-chlorophenyl)sulfanyl-2-methylindol-1-yl]acetic acid Chemical compound C1=2C(NC(=O)C)=CC=CC=2N(CC(O)=O)C(C)=C1SC1=CC=C(Cl)C=C1 JWYIGNODXSRKGP-UHFFFAOYSA-N 0.000 description 1
- VXYDHPDQMSVQCU-UHFFFAOYSA-N 2-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)piperidin-1-yl]-n-hydroxyacetamide Chemical compound COC1=CC=C(C2(CCN(CC(=O)NO)CC2)C#N)C=C1OC1CCCC1 VXYDHPDQMSVQCU-UHFFFAOYSA-N 0.000 description 1
- YANGEESWIGIKOP-UUWRZZSWSA-N 2-[[(2r)-1-[4-[4-[3-(azepan-1-yl)propoxy]phenyl]butyl]pyrrolidin-2-yl]methyl]-4-[(4-chlorophenyl)methyl]phthalazin-1-one Chemical compound C1=CC(Cl)=CC=C1CC(C1=CC=CC=C1C1=O)=NN1C[C@@H]1N(CCCCC=2C=CC(OCCCN3CCCCCC3)=CC=2)CCC1 YANGEESWIGIKOP-UUWRZZSWSA-N 0.000 description 1
- UXVCSPSWUNMPMT-UHFFFAOYSA-N 2-bromo-2,3-dihydroinden-1-one Chemical compound C1=CC=C2C(=O)C(Br)CC2=C1 UXVCSPSWUNMPMT-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- AFTCWZSEWTXWTL-BTQNPOSSSA-N 2-hydroxy-n,n-dimethyl-3-[[2-[[(1r)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobuten-1-yl]amino]benzamide;hydrate Chemical compound O.N([C@H](CC)C=1OC(C)=CC=1)C(C(C1=O)=O)=C1NC1=CC=CC(C(=O)N(C)C)=C1O AFTCWZSEWTXWTL-BTQNPOSSSA-N 0.000 description 1
- JJKWHOSQTYYFAE-UHFFFAOYSA-N 2-methoxyacetyl chloride Chemical compound COCC(Cl)=O JJKWHOSQTYYFAE-UHFFFAOYSA-N 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- BKLAJZNVMHLXAP-VKGMXUHCSA-N 3-[(1r,5s)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl]-2,2-diphenylpropanenitrile Chemical compound C([C@H]1CC[C@@H](C2)[N+]1(C)C)C2CC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 BKLAJZNVMHLXAP-VKGMXUHCSA-N 0.000 description 1
- FUQNVLVKZFXFNI-UHFFFAOYSA-N 3-[4-[4-[4-[4-(3,3-dimethylpiperidin-1-yl)butoxy]phenyl]piperidine-1-carbonyl]naphthalen-1-yl]propanoic acid Chemical compound C1C(C)(C)CCCN1CCCCOC1=CC=C(C2CCN(CC2)C(=O)C=2C3=CC=CC=C3C(CCC(O)=O)=CC=2)C=C1 FUQNVLVKZFXFNI-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- RIGUHSKPKSHQOK-UHFFFAOYSA-N 3-oxoheptanenitrile Chemical compound CCCCC(=O)CC#N RIGUHSKPKSHQOK-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- LCGDIGKSZFHBGH-UHFFFAOYSA-N 3-tert-butylsulfanyl-2,3-dihydroinden-1-one Chemical compound C1=CC=C2C(SC(C)(C)C)CC(=O)C2=C1 LCGDIGKSZFHBGH-UHFFFAOYSA-N 0.000 description 1
- MTVKKPMYQIZLJF-UHFFFAOYSA-N 4-ethoxymorpholine Chemical compound CCON1CCOCC1 MTVKKPMYQIZLJF-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- IHOXNOQMRZISPV-YJYMSZOUSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]azaniumyl]ethyl]-2-oxo-1h-quinolin-8-olate Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 IHOXNOQMRZISPV-YJYMSZOUSA-N 0.000 description 1
- XDBHURGONHZNJF-UHFFFAOYSA-N 6-[2-(3,4-diethoxyphenyl)-1,3-thiazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=C(OCC)C(OCC)=CC=C1C1=NC(C=2N=C(C=CC=2)C(O)=O)=CS1 XDBHURGONHZNJF-UHFFFAOYSA-N 0.000 description 1
- JFHROPTYMMSOLG-UHFFFAOYSA-N 6-[3-(dimethylcarbamoyl)phenyl]sulfonyl-4-(3-methoxyanilino)-8-methylquinoline-3-carboxamide Chemical compound COC1=CC=CC(NC=2C3=CC(=CC(C)=C3N=CC=2C(N)=O)S(=O)(=O)C=2C=C(C=CC=2)C(=O)N(C)C)=C1 JFHROPTYMMSOLG-UHFFFAOYSA-N 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 102100022278 Arachidonate 5-lipoxygenase-activating protein Human genes 0.000 description 1
- 101710187011 Arachidonate 5-lipoxygenase-activating protein Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- PJFHZKIDENOSJB-UHFFFAOYSA-N Budesonide/formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=CC2(C)C2C1C1CC3OC(CCC)OC3(C(=O)CO)C1(C)CC2O PJFHZKIDENOSJB-UHFFFAOYSA-N 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 description 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 1
- ZWOHNLZVAYUOHJ-UHFFFAOYSA-N CC(C)(C)c(cc1N)n[n]1-c1cc(OCCN(C)C)ccc1 Chemical compound CC(C)(C)c(cc1N)n[n]1-c1cc(OCCN(C)C)ccc1 ZWOHNLZVAYUOHJ-UHFFFAOYSA-N 0.000 description 1
- AXPNEHGKCSGSSK-ANYOKISRSA-N CC(C)c1nnc(cc2)[n]1cc2O[C@@H](CC1)c2ccccc2C1NC(NC1CC1)=O Chemical compound CC(C)c1nnc(cc2)[n]1cc2O[C@@H](CC1)c2ccccc2C1NC(NC1CC1)=O AXPNEHGKCSGSSK-ANYOKISRSA-N 0.000 description 1
- NROHTEKSVGTFDD-IRXDYDNUSA-N CC(C)c1nnc(cc2)[n]1cc2O[C@@H](CC1)c2ccccc2[C@H]1N Chemical compound CC(C)c1nnc(cc2)[n]1cc2O[C@@H](CC1)c2ccccc2[C@H]1N NROHTEKSVGTFDD-IRXDYDNUSA-N 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- 101100026251 Caenorhabditis elegans atf-2 gene Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229940098777 Corticosteroid agonist Drugs 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- DVMKZYIJRDRUEN-UHFFFAOYSA-N Fc1c[n]2c(Br)nnc2cc1 Chemical compound Fc1c[n]2c(Br)nnc2cc1 DVMKZYIJRDRUEN-UHFFFAOYSA-N 0.000 description 1
- KINWYTAUPKOPCQ-YFKPBYRVSA-N Fudosteine Chemical compound OC(=O)[C@@H](N)CSCCCO KINWYTAUPKOPCQ-YFKPBYRVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 108010084680 Heterogeneous-Nuclear Ribonucleoprotein K Proteins 0.000 description 1
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 description 1
- 101710141394 MAP kinase-activated protein kinase 2 Proteins 0.000 description 1
- 229940123313 MCP-1 antagonist Drugs 0.000 description 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
- 101710187853 Macrophage metalloelastase Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- HPOXLSCWXAMBEZ-UHFFFAOYSA-N N=C(c1ccnc(N2CCCC2)c1)N(C=C(C=C1)F)C1=N Chemical compound N=C(c1ccnc(N2CCCC2)c1)N(C=C(C=C1)F)C1=N HPOXLSCWXAMBEZ-UHFFFAOYSA-N 0.000 description 1
- JKXLXILEAPGCNY-UHFFFAOYSA-N N=Cc1cccc(OCCN2CCOCC2)c1 Chemical compound N=Cc1cccc(OCCN2CCOCC2)c1 JKXLXILEAPGCNY-UHFFFAOYSA-N 0.000 description 1
- SBSMSVVMZLWVMC-UHFFFAOYSA-N NC=1NC=2C(=C(C1C)Br)C=CC=CC2 Chemical compound NC=1NC=2C(=C(C1C)Br)C=CC=CC2 SBSMSVVMZLWVMC-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- DNXKFRDGTBJAEI-UHFFFAOYSA-N O=C(C#N)CCC.CC(C(CC#N)=O)(C)C Chemical compound O=C(C#N)CCC.CC(C(CC#N)=O)(C)C DNXKFRDGTBJAEI-UHFFFAOYSA-N 0.000 description 1
- CCEWYRVYLKOWSW-UHFFFAOYSA-N OS(C1=CC=C(C=CC=C2)C2=C1S(O)(=O)=O)(=O)=O.N Chemical compound OS(C1=CC=C(C=CC=C2)C2=C1S(O)(=O)=O)(=O)=O.N CCEWYRVYLKOWSW-UHFFFAOYSA-N 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229940126033 PPAR agonist Drugs 0.000 description 1
- 108010015181 PPAR delta Proteins 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 108010000303 Secretory Proteinase Inhibitory Proteins Proteins 0.000 description 1
- 102000002255 Secretory Proteinase Inhibitory Proteins Human genes 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- CWRNUVNMUYSOFQ-ABHLOGGPSA-M [Br-].C[N+]1(C)[C@@H]2CC[C@H]1C[C@H](CC(C#N)(c3ccccc3)c4ccccc4)C2 Chemical compound [Br-].C[N+]1(C)[C@@H]2CC[C@H]1C[C@H](CC(C#N)(c3ccccc3)c4ccccc4)C2 CWRNUVNMUYSOFQ-ABHLOGGPSA-M 0.000 description 1
- YJTXQLYMECWULH-UHFFFAOYSA-O [NH3+]c(nc1)ccc1F Chemical compound [NH3+]c(nc1)ccc1F YJTXQLYMECWULH-UHFFFAOYSA-O 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 229940019903 aclidinium Drugs 0.000 description 1
- 229960005012 aclidinium bromide Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940090167 advair Drugs 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 description 1
- 229960005174 ambroxol Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- YCNIBOIOWCTRCL-UHFFFAOYSA-N azane;2,2,2-trifluoroacetic acid Chemical compound [NH4+].[O-]C(=O)C(F)(F)F YCNIBOIOWCTRCL-UHFFFAOYSA-N 0.000 description 1
- NHJPVZLSLOHJDM-UHFFFAOYSA-N azane;butanedioic acid Chemical compound [NH4+].[NH4+].[O-]C(=O)CCC([O-])=O NHJPVZLSLOHJDM-UHFFFAOYSA-N 0.000 description 1
- QHYIGPGWXQQZSA-UHFFFAOYSA-N azane;methanesulfonic acid Chemical compound [NH4+].CS([O-])(=O)=O QHYIGPGWXQQZSA-UHFFFAOYSA-N 0.000 description 1
- GKOOKSYOGOHELU-UHFFFAOYSA-N azane;naphthalene-1-carboxylic acid Chemical compound [NH4+].C1=CC=C2C(C(=O)[O-])=CC=CC2=C1 GKOOKSYOGOHELU-UHFFFAOYSA-N 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- WQAQPCDUOCURKW-UHFFFAOYSA-N butanethiol Chemical group CCCCS WQAQPCDUOCURKW-UHFFFAOYSA-N 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 229950010713 carmoterol Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 229950001653 cilomilast Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- IRUNKQSGDBYUDC-UHFFFAOYSA-N diethoxymethyl acetate Chemical compound CCOC(OCC)OC(C)=O IRUNKQSGDBYUDC-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FVTWTVQXNAJTQP-UHFFFAOYSA-N diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol Chemical compound C=1C=CC=CC=1C(C12CC[N+](CCOCC=3C=CC=CC=3)(CC1)CC2)(O)C1=CC=CC=C1 FVTWTVQXNAJTQP-UHFFFAOYSA-N 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229960000533 dornase alfa Drugs 0.000 description 1
- 108010067396 dornase alfa Proteins 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000004175 fluorobenzyl group Chemical group 0.000 description 1
- 229960001469 fluticasone furoate Drugs 0.000 description 1
- XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229960000193 formoterol fumarate Drugs 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 235000010985 glycerol esters of wood rosin Nutrition 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- GMXFZBZOVZOYNQ-UHFFFAOYSA-N hydron;(3-methoxyphenyl)hydrazine;chloride Chemical compound Cl.COC1=CC=CC(NN)=C1 GMXFZBZOVZOYNQ-UHFFFAOYSA-N 0.000 description 1
- IKGLACJFEHSFNN-UHFFFAOYSA-N hydron;triethylazanium;trifluoride Chemical compound F.F.F.CCN(CC)CC IKGLACJFEHSFNN-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000035874 hyperreactivity Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 235000013847 iso-butane Nutrition 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229940054136 kineret Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003591 leukocyte elastase inhibitor Substances 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229940127212 long-acting beta 2 agonist Drugs 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 208000007892 occupational asthma Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008723 osmotic stress Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 102000017953 prostanoid receptors Human genes 0.000 description 1
- 108050007059 prostanoid receptors Proteins 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004938 stress stimulation Effects 0.000 description 1
- 238000012437 strong cation exchange chromatography Methods 0.000 description 1
- 238000002305 strong-anion-exchange chromatography Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229940035073 symbicort Drugs 0.000 description 1
- PJFHZKIDENOSJB-JIVDDGRNSA-N symbicort inhalation aerosol Chemical compound C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O PJFHZKIDENOSJB-JIVDDGRNSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229950002896 tetomilast Drugs 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 239000003769 thromboxane A2 receptor blocking agent Substances 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229960004764 zafirlukast Drugs 0.000 description 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
- 229960005332 zileuton Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
公开了具有[1,2,4]三唑并[4,3-a]吡啶基团的化合物及其药学上可接受的盐。所述化合物是p38MAPK抑制剂,其可在呼吸道疾病以及其它疾病的治疗中用作抗炎剂。
Description
技术领域
本发明涉及作为p38MAPK抑制剂的化合物和组合物,它们在呼吸道疾病以及其它疾病的治疗中用作抗炎剂。
背景技术
促分裂原活化蛋白激酶(MAPK)构成针对脯氨酸的丝氨酸/苏氨酸激酶家族,它们通过双重磷酸化来活化它们的底物。p38MAP激酶存在4种已知的人类同种型:p38α、p38β、p38γ和p38δ。p38激酶(它们也称作细胞因子抑制性的抗炎药物结合蛋白(CSBP)、应激活化蛋白激酶(SAPK)和RK)负责磷酸化(Stein等人,Ann.Rep.MedChem.,1996,31,289-298)和活化转录因子(诸如ATF-2、MAX、CHOP和C/ERPb)以及其它激酶(诸如MAPKAP-K2/3或MK2/3),且它们自身被物理和化学应激(例如紫外线、渗透性应激)、促炎细胞因子和细菌脂多糖(LPS)活化(HerlaarE.&BrownZ.,MolecularMedicineToday,1999,5,439-447)。已经证实,p38磷酸化的产物会介导炎性细胞因子(包括肿瘤坏死因子α(TNFα)、白介素-(IL-)-1和环加氧酶-2(COX-2))的生成。还已知IL-1和TNFα会刺激其它促炎细胞因子(诸如IL-6和IL-8)的生成。
IL-1和TNFα是由多种细胞(诸如单核细胞或巨噬细胞)生成的生物物质。已经证实,IL-1会介导多种被认为对于免疫调节和其它生理状态(诸如炎症)而言重要的生物活性(例如Dinarello等人,Rev.Infect.Disease,1984,6,51)。过度的或失调的TNF生成(尤其是TNFα)已经牵涉介导或加重许多疾病,且认为,TNF可以造成或促成一般的炎症效应。IL-8是由几种细胞类型(包括单核细胞、成纤维细胞、内皮细胞和角质化细胞)生成的趋化因子。它从内皮细胞的生成是由IL-1、TNF或脂多糖(LPS)诱导。IL-8在体外会刺激许多功能。已经证实,它对于嗜中性粒细胞、T-淋巴细胞和嗜碱性粒细胞具有化学引诱物性质。IL-8生成的增加也会引起嗜中性粒细胞向体内炎症部位的趋化性。
几种其它促炎蛋白(例如,IL-6、GM-CSF、COX-2、胶原酶和溶基质蛋白酶)的合成和/或作用也需要通过p38(以及上述的IL-1、TNF和IL-8)来抑制信号转导,预期是用于调节免疫系统的过度和破坏性活化的高度有效的机制。该预期得到了关于p38激酶抑制剂所描述的有效且不同的抗炎活性的支持(Badger等人,J.Pharm.Exp.Thera.,1996,279,1453-1461;Griswold等人,Pharmacol.Comm.,1996,7,323-229)。具体地,已经将p38激酶抑制剂描述为类风湿性关节炎的潜在治疗剂。除了p38活化与慢性炎症和关节炎之间的联系以外,也有数据提示p38在气道疾病(尤其是COPD和哮喘)的发病机制中的作用。应激刺激(包括烟草烟雾、感染或氧化产物)可以造成肺环境内的炎症。已经证实,p38的抑制剂会抑制LPS和卵白蛋白诱导的气道TNF-α、IL-1β、IL-6、IL-4、IL-5和IL-13(Haddad等人,Br.J.Pharmacol.,2001,132(8),1715-1724;Underwood等人,Am.J.Physiol.LungCell.Mol.2000,279,895-902;Duan等人,2005Am.J.Respir.Crit.CareMed.,171,571-578;Escott等人Br.J.Pharmacol.,2000,131,173-176;Underwood等人,J.Pharmacol.Exp.Ther.2000,293,281-288)。此外,它们在LPS、臭氧或香烟烟雾动物模型中显著抑制嗜中性粒细胞增多症和MMP-9的释放。还有大量临床前数据证实了与肺有关的抑制p38激酶的潜在益处(Lee等人,Immunopharmacology,2000,47,185-200)。因而,p38活化的治疗性抑制可能在气道炎症的调节中是重要的。
P.Chopra等人已经综述了p38MAPK途径在不同疾病中的牵涉(ExpertOpiniononInvestigationalDrugs,2008,17(10),1411-1425)。据信,本发明的化合物可用于治疗p38介导的疾病,诸如:哮喘、慢性或急性支气管收缩、支气管炎、急性肺损伤及支气管扩张、肺动脉高压(pulmonaryarteryhypertension)、肺结核、肺癌、一般性炎症(例如炎性肠病)、关节炎、神经炎症、疼痛、发热、纤维变性疾病、肺障碍及疾病(例如,氧过多肺泡损伤)、心血管疾病、缺血后再灌注损伤及充血性心脏衰竭、心肌病、中风、缺血、再灌注损伤、肾再灌注损伤、脑水肿、神经创伤以及脑创伤、神经变性障碍、中枢神经系统障碍、肝疾病及肾炎、胃肠病症、溃疡疾病、局限性回肠炎、眼疾病、眼科病症、青光眼、眼睛组织的急性损伤以及眼创伤、糖尿病、糖尿病性肾病、皮肤有关的病症、因为感染引起的肌痛、流行性感冒、内毒素性休克、中毒性休克综合征、自身免疫疾病、移植物排斥、骨吸收疾病、多发性硬化、银屑病、湿疹、女性生殖系统的障碍、病理(但非恶性)病症(诸如,血管瘤、鼻咽的血管纤维瘤及骨缺血性坏死)、良性及恶性肿瘤/瘤形成(包括癌症、白血病、淋巴瘤)、系统性红斑性狼疮(SLE)、血管生成(包括瘤形成)、出血、凝固、辐射损伤和/或转移。活性TNF的慢性释放可造成恶病质及厌食,并且TNF可以致命。TNF也已经牵涉感染性疾病。这些疾病包括,例如,疟疾、分枝杆菌感染及脑膜炎。这些也包括病毒感染,例如HIV、流行性感冒病毒和疱疹病毒(包括1型单纯疱疹病毒(HSV-1)、2型单纯疱疹病毒(HSV-2)、巨细胞病毒(CMV)、水痘-带状疱疹病毒(VZV)、非洲淋巴细胞瘤病毒、人类疱疹病毒6(HHV-6)、人类疱疹病毒7(HHV-7)、人类疱疹病毒8(HHV-8));假性狂犬病及鼻气管炎等。
G.J.Hanson(ExpertOpinionsonTherapeuticPatents,1997,7,729-733)、JHynes等人(CurrentTopicsinMedicinalChemistry,2005,5,967-985)、C.Dominguez等人(ExpertOpinionsonTherapeuticsPatents,2005,15,801-816)以及L.H.Pettus和R.P.Wurtz(CurrentTopicsinMedicinalChemistry,2008,8,1452-1467)已经综述了已知的P38激酶抑制剂。含有三唑并吡啶基序的P38激酶抑制剂是本领域已知的,例如WO07/091152、WO04/072072、WO06/018727。
发明概述
本发明的化合物是包括p38α激酶在内的p38促分裂原活化蛋白激酶(“p38MAPK”、“p38激酶”或“p38”)的抑制剂,且是细胞因子和趋化因子生成(包括TNFα和IL-8生成)的抑制剂。它们具有许多治疗用途,用于治疗炎性疾病、尤其是变应性和非变应性气道疾病、更特别是阻塞性或炎性气道疾病诸如慢性阻塞性肺疾病(“COPD”)和哮喘。它们因此特别适合肺递送(通过鼻或嘴吸入)。
发明内容
除了别的以外,我们的共同未决的国际专利申请号PCT/GB2011/051076涉及作为p38MAPK抑制剂的式(I)的化合物,其可在呼吸道疾病以及其它疾病的治疗中用作抗炎剂:
其中:
R1是式(IA)或(IB)或(IC)的残基:
其中
R4b是C1-C6烷基、C3-C6环烷基、任选地被取代的苯基、任选地被取代的5或6元单环杂芳基或式(IIa)或(IIb)的残基
其中n是1或2;且R3和R4独立地是H或C1-C6烷基,或R3和R4与它们所连接的氮一起形成6元杂环,所述杂环任选地含有选自N和O的另外的杂原子;
R3b是任选地被取代的C1-C6烷基;-NH2;单-或二-(C1-C6)烷基氨基;单-或二-(C1-C3)烷基-X-(C1-C3)烷基氨基,其中X是O、S或NH;N-吗啉代;N-哌啶基、N-哌嗪基或N-(C1-C3)烷基哌嗪-1-基;
Y是-O-或-S(O)p-,其中p是0、1或2;
A是与苯环稠合的、任选地被取代的具有5、6或7个环原子的亚环烷基残基;
R2是式(IIIa)、(IIIb)、(IIIc)、(IIId)或(IIIe)的残基:
其中
q是0、1、2或3;
T是-N=或-CH=;
R5是H或F;
R7是-CH3;-C2H5;-CH2OH、-CH2SCH3;-SCH3或-SC2H5;
R8是-CH3或-C2H5;且
每次出现的R6独立地是H、C1-C6烷基、羟基或卤素(halo);或单次出现的R6是式(IVa)、(IVb)或(IVc)的残基
同时任何其它出现的R6独立地是H、C1-C6烷基、羟基或卤素;
其中在式(IVa)、(IVb)和(IVc)中,n和p如上面所定义;
且其中在R6中
R61a和R61b是H、烷基,或R61a和R61b可以与它们所连接的氮连接到一起以形成4-7元杂环,所述杂环任选地含有选自N和O的另外的杂原子,诸如哌啶、哌嗪或吗啉环。
本发明涉及落入No.PCT/GB2011/051076的式(I)范围内、但是在其中没有具体公开的作为p38MAPK抑制剂的化合物。
发明详述
根据本发明,提供了选自以下的化合物:
1-(5-叔丁基-2-苯基-2H-吡唑-3-基)-3-[4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-环丙基-3-[4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[3-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基硫烷基(sulfanyl))-茚满-1-基]-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[4-{3-[3-(2-吗啉-4-基-乙氧基)-苯基]-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基}-1,2,3,4-四氢-萘-1-基)-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-7-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-{5-叔丁基-2-[3-(2-吗啉-4-基-乙氧基)-苯基]-2H-吡唑-3-基}-3-[4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-{4-(3-(2-羟基-苯基)-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基}-脲;
1-(5-叔丁基-异噁唑-3-基)-3-[3-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-茚满-1-基]-脲;
N-(4-{4-[3-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-脲基]-1,2,3,4-四氢-萘-1-基氧基甲基}-吡啶-2-基)-2-甲氧基-乙酰胺;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-{4-[3-(2-羟基-乙基硫烷基)-苯基]-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基-脲;
1-{5-叔丁基-2-[3-(2-二甲基氨基-乙氧基)-苯基]-2H-吡唑-3-基}-3-[4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-[5-叔丁基-2-(4-羟基-苯基)-2H-吡唑-3-基]-3-[4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[4-(3-叔丁基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-(5-叔丁基-异噁唑-3-基)-3-[4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[4-(3-环戊基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-[5-叔丁基-2-(3-吗啉-4-基甲基-苯基)-2H-吡唑-3-基]-3-[4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基-3-{4-(3-(2,6-二氯-苯基)-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基}-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[4-(3-环丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基}-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[4-(3-吡啶-2-基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基}-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基-3-{4-(3-(2-氯-苯基)-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基}-脲;
1-{4-[3-(2-苄氧基-苯基)-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基}-3-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-脲;
1-[5-叔丁基-2-(3-氯-4-羟基-苯基)-2H-吡唑-3-基]-3-[4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[4-(3-环己基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-[5-叔丁基-2-(4-氯-3-羟基-苯基)-2H-吡唑-3-基]-3-[4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
N-(5-叔丁基-3-{3-[4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲基}-2-甲氧基-苯基)-甲磺酰胺;
1-(3-氟-5-吗啉-4-基-苯基)-3-[4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-{5-叔丁基-2-(4-氟-3-吗啉-4-基甲基-苯基)-2H-吡唑-3-基}-3-[4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-[5-叔丁基-2-(3-氯-4-羟基-苯基)-2H-吡唑-3-基]-3-(4-{3-[2-(2-羟基-乙基硫烷基)-苯基]-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基}-1,2,3,4-四氢-萘-1-基)-脲;
1-[5-叔丁基-2-(3-氯-4-羟基-苯基)-2H-吡唑-3-基]-3-(4-{3-[2-(2-羟基-乙基硫烷基)-苯基]-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基}-1,2,3,4-四氢-萘-1-基)-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-{(4-[3-(2-吡咯烷-1-基-吡啶-4-基)-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基]-1,2,3,4-四氢-萘-1-基}-脲;
和它们的药学上可接受的盐。
具体地,本发明提供了选自以下的化合物:在下表中列出的那些,或其药学上可接受的盐:
(续)
(续)
在另一个方面,本发明包括药物组合物,其含有本发明化合物以及一种或多种药学上可接受的载体和/或赋形剂。特别优选的是适合吸入进行肺给药的组合物。
在另一个方面,本发明包括本发明化合物用于治疗受益于p38MAP激酶活性抑制的疾病或病症的用途。优选的用途为阻塞性或炎性气道疾病的治疗。使用本发明的化合物可潜在地治疗所有形式的阻塞性或炎性气道疾病,尤其是选自下列的阻塞性或炎性气道疾病:慢性嗜酸粒细胞性肺炎,哮喘,COPD,包括慢性支气管炎、肺气肿或与COPD有关或无关的呼吸困难的COPD,以不可逆的进行性气道阻塞为特征的COPD,成人呼吸窘迫综合征(ARDS),因其它药物治疗所发生的气道高反应性(hyper-reactivity)的恶化,以及与肺动脉高压(pulmonaryhypertension)有关的气道疾病,包括囊性纤维化病在内的慢性炎性疾病,支气管扩张和肺纤维化(特发性的)。当局部地向肺(例如通过吸入和鼻内递送)或通过全身途径(例如,口服、静脉内和皮下递送)施用p38激酶抑制剂时,预见到效力。
本发明的化合物可能以一种或多种几何异构、光学异构、对映异构、非对映异构和互变异构的形式存在,包括但不限于顺式和反式形式、E-和Z-形式、R-、S-和内消旋形式、酮-和烯醇-形式。除非另有说明,提及的特定化合物包括所有这样的异构形式,包括其外消旋形式和其它混合物。在适当时,通过应用或采用已知的方法(例如色谱技术和重结晶技术),可以从它们的混合物中分离出这样的异构体。在适当时,通过应用或采用已知的方法(例如不对称合成),可以制备这样的异构体。
本文使用的术语“盐”包括碱加成盐、酸加成盐和铵盐。本发明的酸性化合物可与碱形成盐,包括药学上可接受的盐,所述碱例如:碱金属氢氧化物,例如氢氧化钠和氢氧化钾;碱土金属氢氧化物,例如氢氧化钙、氢氧化钡和氢氧化镁;有机碱,例如N-甲基-D-葡糖胺、胆碱三(羟甲基)氨基-甲烷、L-精氨酸、L-赖氨酸、N-乙基哌啶、二苄胺等。本发明的那些碱性化合物可与无机酸和有机酸形成盐,包括药学上可接受的盐,所述无机酸例如氢卤酸,例如氢氯酸或氢溴酸、硫酸、硝酸或磷酸等,所述有机酸例如乙酸、三氟乙酸、酒石酸、琥珀酸、富马酸、马来酸、苹果酸、水杨酸、柠檬酸、甲磺酸、对甲苯磺酸、苯甲酸、苯磺酸、谷氨酸、乳酸和扁桃酸等。本发明的具有碱性氮的那些化合物也可以与药学上可接受的抗衡离子形成季铵盐,诸如氯化铵、溴化铵、乙酸铵、甲酸铵、对甲苯磺酸铵、琥珀酸铵、半-琥珀酸铵、萘-二磺酸铵、甲磺酸铵、三氟乙酸铵、昔萘酸铵等。关于盐的综述,参见Stahl和Wermuth的HandbookofPharmaceuticalSalts:Properties,Selection,andUse(Wiley-VCH,Weinheim,Germany,2002)。
预见到,本发明的化合物可以以水合物和溶剂合物的形式制备。在本文中,包括在本文的权利要求中提及的任意“本发明有关的化合物”或“本发明的化合物”或“本发明化合物”等,都包括这样的化合物的盐、水合物和溶剂合物。术语‘溶剂合物’在本文中用于描述这样的分子复合物,其包含本发明的化合物和化学计量量的一种或多种药学上可接受的溶剂分子,例如乙醇。当所述溶剂是水时,使用术语‘水合物’。
本发明的个别化合物可以以几种多晶型存在,且可以以不同的晶体习性得到。
所述化合物也可以以其前药的形式施用。因此,可能自身是有活性的或可能本身几乎不具有或根本不具有药理学活性的某些化合物衍生物在施用进体内或到体表上时,可以转化为具有希望的活性的本发明的化合物,例如,通过水解裂解。这类衍生物称作为‘前药’。关于前药的应用的进一步信息,可以参见:Pro-drugsasNovelDeliverySystems,Vol.14,ACSSymposiumSeries(T.Higuchi和V.J.Stella)和BioreversibleCarriersinDrugDesign,PergamonPress,1987(E.B.Roche编,AmericanPharmaceuticalAssociation;C.S.Larsen和J.Designandapplicationofprodrugs,见TextbookofDrugDesignandDiscovery,第3版,2002,TaylorandFrancis)。
例如,通过用本领域技术人员已知的称作为‘前部分(pro-moieties)’的某些部分(例如,在H.Bundgaard的DesignofProdrugs(Elsevier,1985)中所描述的)替换在本发明的化合物中存在的适当官能团,可以制备根据本发明的前药。
具体实施方式
在一个实施方案中,本发明的化合物是式(Ia)的化合物或其药学上可接受的盐:
其中基团R1选自:
-3-[3-(2-吗啉-4-基-乙氧基)-苯基]-[1,2,4]三唑并[4,3-a]吡啶-6-基;
-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-7-基;
-3-(2-羟基-苯基)-[1,2,4]三唑并[4,3-a]吡啶-6-基;
-{2-[(甲氧基乙酰基)氨基]吡啶-4-基}甲基;
-3-[3-(2-羟基-乙基硫烷基)-苯基]-[1,2,4]三唑并[4,3-a]吡啶-6-基;
-3-叔丁基-[1,2,4]三唑并[4,3-a]吡啶-6-基;
-3-环戊基-[1,2,4]三唑并[4,3-a]吡啶-6-基;
-3-(2,6-二氯-苯基)-[1,2,4]三唑并[4,3-a]吡啶-6-基;
-3-环丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基;
-3-吡啶-2-基-[1,2,4]三唑并[4,3-a]吡啶-6-基;
-3-(2-氯-苯基)-[1,2,4]三唑并[4,3-a]吡啶-6-基;
-3-(2-苄氧基-苯基)-[1,2,4]三唑并[4,3-a]吡啶-6-基;
-3-环己基-[1,2,4]三唑并[4,3-a]吡啶-6-基;
-3-(2-吡咯烷-1-基-吡啶-4-基)-[1,2,4]三唑并[4,3-a]吡啶-6-基。
在一个实施方案中,提供了式(Ia1)的化合物,其为如上定义的式(Ia)的化合物,其中用编号(1)标识的碳立体中心(stereogeniccenter)具有下文表示的绝对构型:
在一个优选的实施方案中,提供了式(Ia2)的化合物,其为如上定义的式(Ia)的化合物,其中用编号(1)和(2)标识的碳立体中心具有下文表示的绝对构型:
在另一个实施方案中,本发明的化合物是式(Ib)的化合物或其药学上可接受的盐:
其中基团R2选自:
-5-叔丁基-2-苯基-2H-吡唑-3-基;
-环丙基;
-5-叔丁基-2-[3-(2-吗啉-4-基-乙氧基)-苯基]-2H-吡唑-3-基;
-5-叔丁基-2-[3-(2-二甲基氨基-乙氧基)-苯基]-2H-吡唑-3-基;
-5-叔丁基-2-(3-氯-4-羟基-苯基)-2H-吡唑-3-基;
-5-叔丁基-2-(4-氯-3-羟基苯基)-2H-吡唑-3-基;
-5-叔丁基-2-(4-羟基-苯基)-2H-吡唑-3-基;
-5-叔丁基-异噁唑-3-基;
-5-叔丁基-2-(3-吗啉-4-基甲基-苯基)-2H-吡唑-3-基;
-5-叔丁基-3-甲磺酰基氨基-2-甲氧基-苯基;3-氟-5-吗啉-4-基-苯基;
-5-叔丁基-2-(4-氟-3-吗啉-4-基甲基-苯基)-2H-吡唑-3-基;
在一个实施方案中,提供了式(Ib1)的化合物,其为如上定义的式(Ib)的化合物,其中用编号(1)标识的碳立体中心具有下文表示的绝对构型:
在一个优选的实施方案中,提供了式(Ib2)的化合物,其为如上定义的式(Ib)的化合物,其中用编号(1)和(2)标识的碳立体中心具有下文表示的绝对构型:
在另一个实施方案中,提供了式(Ib3)的化合物,其为如上定义的式(Ib3)的化合物,其中用编号(1)和(2)标识的碳立体中心具有下文表示的绝对构型:
实用性
如上所述,本发明的化合物是p38MAPK抑制剂,因而可以用于治疗受益于p38酶的抑制的疾病或病症。这样的疾病和病症可从文献中获知,且在上面已经提到几种。但是,所述化合物通常用作抗炎剂,尤其是用于治疗呼吸性疾病。具体地,所述化合物可以用于治疗慢性阻塞性肺疾病(COPD)、慢性支气管炎、肺纤维化、肺炎、急性呼吸窘迫综合征(ARDS)、肺气肿或吸烟诱发的肺气肿、固有的(非变应性的哮喘)和非固有的(变应性的)哮喘、轻度哮喘、中度哮喘、严重哮喘、类固醇抵抗型哮喘、嗜中性粒细胞性哮喘、支气管炎性哮喘、运动诱发的哮喘、职业性哮喘和细菌感染后诱发的哮喘、囊性纤维化病、肺纤维化和支气管扩张。
本发明提供了本发明的化合物用于预防和/或治疗受益于p38酶的抑制的任意疾病或病症的用途。
在另一个方面,本发明提供了本发明的化合物用于制备药物的用途,所述药物用于预防和/或治疗受益于p38酶的抑制的任意疾病或病症。
此外,本发明提供了一种用于预防和/或治疗受益于p38酶的抑制的任意疾病的方法,所述方法包括:给需要这种治疗的患者施用治疗有效量的本发明的化合物。
组合物
如上所述,本发明涉及的化合物是p38激酶抑制剂,且可用于治疗几种疾病,例如呼吸道的炎性疾病。这样的疾病的实例在上面有所提及,包括哮喘、鼻炎、变应性气道综合征、支气管炎和慢性阻塞性肺疾病。
应当理解,任意特定患者的具体剂量水平取决于多种因素,包括使用的具体化合物的活性、年龄、体重、一般健康、性别、饮食、给药时间、给药途径、排泄速率、药物联合以及正在治疗的特定疾病的严重性。如药学领域所要求的,通过临床试验确定给药的最佳剂量水平和频率。一般而言,对于口服给药,按照单次或分份剂量,日剂量范围是在约0.001mg至约100mg/kg人体重、经常0.01mg至约50mg/kg,例如0.1至10mg/kg的范围内。一般而言,对于吸入给药,按照单次或分份剂量,日剂量范围是在约0.1μg至约1mg/kg人体重、优选0.1μg至50μg/kg的范围内。另一方面,在有些情况下,可能必须使用在这些限度以外的剂量。对于本发明的目的,吸入给药是优选的。
可以制备本发明涉及的化合物,用于通过与它们的药代动力学性质相一致的任意途径进行给药。可口服给药的组合物可以是片剂、胶囊、散剂、颗粒剂、锭剂、液体或凝胶制剂的形式,例如口服的、局部的或无菌的肠胃外溶液或悬浮液。用于口服给药的片剂和胶囊可以是单位剂量呈现形式,并且可含有常规赋形剂,例如:粘合剂,例如糖浆、阿拉伯胶、明胶、山梨醇、黄蓍胶或聚乙烯吡咯烷酮;填充剂,例如乳糖、糖、玉米淀粉、磷酸钙、山梨醇或甘氨酸;压片润滑剂,例如硬脂酸镁、滑石、聚乙二醇或二氧化硅;崩解剂,例如马铃薯淀粉,或可接受的湿润剂,例如月桂基硫酸钠。根据普通医药实践中公知的方法,可以将片剂包衣。口服的液体制剂可以是例如水性或油性悬浮液、溶液、乳剂、糖浆剂或酏剂的形式,或可以作为在使用前用水或其它合适的媒介物重配的干燥产品。这种液体制剂可含有常规的添加剂,例如:助悬剂,例如山梨醇、糖浆剂、甲基纤维素、葡萄糖糖浆剂、明胶、氢化的可食用脂肪;乳化剂,例如卵磷脂、脱水山梨糖醇单油酸酯或阿拉伯胶;非水性媒介物(可包括食用油),例如杏仁油、分馏的椰子油、油性酯(如甘油)、丙二醇或乙醇;防腐剂,例如对羟基苯甲酸甲酯或对羟基苯甲酸丙酯或山梨酸,以及在需要时的常规调味剂或着色剂。
为了局部施用于皮肤,可以将所述药物制成乳膏剂、洗剂或软膏剂。可用于所述药物的乳膏剂或软膏剂制剂是本领域公知的常规制剂,例如如在药剂学的标准教科书(如英国药典)中所述。
活性成分还可在无菌介质中肠胃外地给药。根椐所使用的媒介物和浓度,所述药物可以悬浮或溶解在媒介物中。有利地,还可将佐剂(如局部麻醉剂、防腐剂和缓冲剂)溶解在媒介物中。
但是,对于呼吸道的炎性疾病的治疗,本发明的化合物也可以配制成用于吸入,例如作为鼻喷雾剂、或干粉或气溶胶吸入器。对于吸入递送,活性化合物优选地为微粒形式。通过包括喷雾干燥、冷冻干燥和微粉化在内的多种技术,可以制备这些微粒。使用例如压力驱动的喷射雾化器或超声雾化器,可以产生气溶胶,优选地使用推进剂驱动的定量气溶胶或微粉化的活性化合物的不含推进剂的给药(来自例如吸入式胶囊或其它“干粉”递送系统)。
例如,本发明的组合物可制备为悬浮液用于从喷雾器递送,或制备为液体推进剂中的气溶胶而用于例如加压定量吸入器(PMDI)中。适用于PMDI的推进剂为熟练技术人员所已知,包括CFC-12、HFA-134a、HFA-227、HCFC-22(CCl2F2)和HFA-152(CH4F2和异丁烷)。
在本发明的一个优选实施方案中,本发明的组合物为干粉形式,用于使用干粉吸入器(DPI)的递送。很多类型的DPI是已知的。
可以用辅助递送和释放的赋形剂配制用于给药递送的微粒。例如,在干粉制剂中,可以用有助于从DPI流向肺的大载体颗粒来配制微粒。合适的载体颗粒是已知的,包括乳糖颗粒;它们可具有大于90μm的质量中值直径(massmedianaerodynamicdiameter)。
在基于气溶胶的制剂的情况下,一个实施例是:
可根据所用的吸入器系统,如前所述地给予活性化合物。除了活性化合物之外,给药形式可以额外含有赋形剂,例如,推进剂(例如对于定量气溶胶,可使用氟利昂)、表面活性物质、乳化剂、稳定剂、防腐剂、调味剂、填充剂(例如对于粉末吸入器,可使用乳糖),或者如果合适时,还含有其它活性化合物。
对于吸入目的,可以得到很多种产生和施用具有最合适粒度的气溶胶的系统,其中使用适合患者的吸入技术。除了使用接合管(adaptor)(间隔器(spacer)、扩张器(expander))和梨形容器(例如 )和发射吹气(puffer)喷雾的自动装置之外,对于定量气溶胶,特别是对于粉末吸入器的情况,可以得到很多种技术方案(例如或例如EP-A-0505321所述的吸入器)。另外,本发明的化合物可以在多室装置中递送,从而允许递送联合药剂。
组合
其它化合物可以与本发明涉及的化合物相组合,用于预防和治疗炎性疾病,尤其是呼吸系统疾病。因而,本发明也涉及药物组合物,其包含治疗有效量的本发明化合物和一种或多种其它治疗剂。适用于与本发明化合物联合治疗的治疗剂包括、但不限于:(1)皮质甾类,例如丙酸氟替卡松、糠酸氟替卡松、糠酸莫米松、二丙酸倍氯米松、环索奈德、布地奈德、GSK685698、GSK870086、QAE397、QMF149、TPI-1020;(2)β2-肾上腺素能受体激动剂诸如沙丁胺醇(salbutamol)、沙丁胺醇(albuterol)、特布他林、非诺特罗,和长效β2-肾上腺素能受体激动剂诸如沙美特罗、茚达特罗、福莫特罗(包括富马酸福莫特罗)、阿福特罗、卡莫特罗、GSK642444、GSK159797、GSK159802、GSK597501、GSK678007、AZD3199;(3)皮质甾类/长效β2激动剂组合产品,诸如沙美特罗/丙酸氟替卡松(Advair/Seretide)、福莫特罗/布地奈德(Symbicort)、福莫特罗/丙酸氟替卡松(Flutiform)、福莫特罗/环索奈德、福莫特罗/糠酸莫米松、茚达特罗/糠酸莫米松、茚达特罗/QAE397、GSK159797/GSK685698、GSK159802/GSK685698、GSK642444/GSK685698、GSK159797/GSK870086、GSK159802/GSK870086、GSK642444/GSK870086、阿福特罗/环索奈德;(4)抗胆碱能药,例如毒蕈碱-3(M3)受体拮抗剂诸如异丙托溴铵、噻托溴铵、Aclidinium(LAS-34273)、NVA-237、GSK233705、Darotropium、GSK573719、GSK961081、QAT370、QAX028;(5)双重药理学M3-抗胆碱能/β2-肾上腺素能受体激动剂诸如GSK961081;(6)白三烯调节剂,例如白三烯拮抗剂诸如孟鲁司特、扎鲁司特或普仑司特,或白三烯生物合成抑制剂诸如齐留通或BAY-1005,或LTB4拮抗剂诸如阿美卢班,或FLAP抑制剂诸如GSK2190914、AM-103;(7)磷酸二酯酶-IV(PDE-IV)抑制剂(口服或吸入),例如罗氟司特、西洛司特、奥米司特、ONO-6126、Tetomilast、妥非司特、UK500,001、GSK256066;(8)抗组胺剂,例如选择性的组胺-1(H1)受体拮抗剂,例如非索非那定、citirizine、氯雷他定或阿司咪唑,或双重H1/H3受体拮抗剂诸如GSK835726、GSK1004723;(9)镇咳药,例如可待因或右美沙芬(dextramorphan);(10)粘液溶解剂,例如N乙酰基半胱氨酸或弗多司坦;(11)祛痰药/粘液动力学(mucokinetic)调节剂,例如氨溴素、高渗溶液(例如盐水或甘露醇)或表面活性剂;(12)肽粘液溶解剂,例如重组人脱氧核糖核酶I(阿法链道酶和rhDNA酶)或螺杀菌素;(13)抗生素,例如阿奇霉素、妥布霉素和氨曲南;(14)非选择性的COX-1/COX-2抑制剂,例如布洛芬或酮洛芬;(15)COX-2抑制剂,例如塞来考昔和罗非昔布;(16)VLA-4拮抗剂,例如在WO97/03094和WO97/02289中所述的那些;(17)TACE抑制剂和TNF-α抑制剂,例如抗-TNF单克隆抗体,例如注射用英利昔单抗和CDP-870和TNF受体免疫球蛋白分子,例如Enbrel;(18)基质金属蛋白酶抑制剂,例如MMP-12;(19)人嗜中性粒细胞弹性酶抑制剂,例如ONO-6818或在WO2005/026124、WO2003/053930和WO06/082412中所述的那些;(20)A2b拮抗剂诸如在WO2002/42298中所述的那些;(21)趋化因子受体功能调节剂,例如CCR3和CCR8的拮抗剂;(22)调节其它类前列腺素受体的作用的化合物,例如血栓烷A2拮抗剂;DP1拮抗剂诸如MK-0524,CRTH2拮抗剂诸如ODC9101和AZD1981,和混合的DP1/CRTH2拮抗剂诸如AMG009;(23)PPAR激动剂,包括PPARα激动剂(诸如非诺贝特)、PPARδ激动剂、PPARγ激动剂,例如吡格列酮、罗格列酮和巴格列酮;(24)甲基黄嘌呤诸如茶碱或氨茶碱,和甲基黄嘌呤/皮质甾类组合诸如茶碱/布地奈德、茶碱/丙酸氟替卡松、茶碱/环索奈德、茶碱/糠酸莫米松和茶碱/二丙酸倍氯米松;(25)A2a激动剂诸如在EP1052264和EP1241176中所述的那些;(26)CXCR2或IL-8拮抗剂诸如SCH527123或GSK656933;(27)IL-R信号传递调节剂诸如kineret和ACZ885;(28)MCP-1拮抗剂诸如ABN-912。
本发明也涉及试剂盒,其包含:单独的或与一种或多种药学上可接受的载体和/或赋形剂组合或混合的本发明化合物的药物组合物,和装置,所述装置可以是单次剂量或多次剂量干粉吸入器、定量吸入器或喷雾器。
一般实验细节
在实验部分中使用的缩写:AcOH=乙酸;aq.=水溶液;DCM=二氯甲烷;DIAD=偶氮二甲酸二异丙酯;DIPEA=二异丙基乙胺;DMAP=N,N-二甲基氨基吡啶;DMF=N,N-二甲基甲酰胺;DMSO=二甲亚砜;EDC=1-乙基-3-(3'-二甲基氨基丙基)碳二亚胺盐酸盐;EtOAc=乙酸乙酯;EtOH=乙醇;Et2O=乙醚;Et3N=三乙胺;EtNiPr2=二异丙基乙胺;FCC=快速柱色谱法;h=小时;HATU=2-(7-氮杂-1H-苯并三唑-1-基)-1,1,3,3-四甲基脲鎓六氟磷酸盐;HOBt=1-羟基-苯并三唑;HPLC=高效液相色谱法;IMS=工业用甲醇化酒精;LCMS=液相色谱法质谱法;NaOH=氢氧化钠;MeCN=乙腈;MeOH=甲醇;min(s)=分钟;NH3=氨;NMR=核磁共振;RT=室温;Rt=保留时间;sat.=饱和的;SCX-2=强阳离子交换色谱法;TFA=三氟乙酸;THF=四氢呋喃;H2O=水;IMS=工业用甲醇化酒精;X-Select=WatersX-selectHPLC柱。
在下面的操作中,在每种起始原料后面,有时提供了对化合物编号的提及。这仅仅为了辅助熟练的化学家而提供。所述起始原料不一定已经从提及的批料制备。
当提及使用“类似的”或“相似的”操作时,本领域技术人员会明白,这样的操作可能包含微小变化,例如反应温度、试剂/溶剂量、反应时间、后处理条件或色谱纯化条件。
使用得自MDLInc.的Autonom2000Name软件,指定结构的命名。当使用Autonom不能指定结构的命名时,使用ACD/LabsRelease12.00ProductVersion12.5(Build45133,2010年12月16日)的ACD/Name软件实用程序部分。化合物的立体化学指定(stereochemicalassignment)是基于与在WO2008/043019中关于关键中间体报道的数据的NMR对比。除非另有说明,否则在无水条件和氮或氩气氛下进行所有反应。除非另有说明,否则在环境温度(室温)进行所有转化。
在VarianUnityInova400波谱仪(具有运行在400MHz的5mm倒置检测三共振探头)上,或在BrukerAvanceDRX400波谱仪(具有运行在400MHz的5mm倒置检测三共振TXI探头)上,或在BrukerAvanceDPX300波谱仪(具有运行在300MHz的标准5mm双频率探头)上,得到NMR谱。按照相对于四甲基硅烷(δ=0ppm)的ppm,给出迁移。到处按照Hz给出J值。使用DataChordSpectrumAnalyst4.0.b21版或SpinWorks3版,指定NMR谱。
在通过快速柱色谱法纯化产物的情况下,‘快速硅胶’表示用于色谱法的硅胶,0.035-0.070mm(220-440目)(例如Fluka硅胶60),并施加高达10p.s.i的氮压力来加速柱洗脱,或使用伴侣(Companion)纯化系统或使用BiotageSP1纯化系统。所有溶剂和商业试剂按照接收时的状态使用。
除非另外指出,否则使用C18-反相柱(100×22.5mm内径,Genesis柱,7μm粒度)、或苯基-己基柱(250×21.2mm内径,Gemini柱,5μm粒度),纯化通过制备型HPLC纯化的化合物,在220-254nm之间紫外检测,流速5-20mL/min,用100-0至0-100%水/乙腈(含有0.1%TFA或0.1%甲酸)或水/MeOH(含有0.1%TFA或0.1%甲酸)进行梯度洗脱。合并含有所需产物的级分(通过LCMS分析鉴别),通过蒸发除去有机溶剂,将剩余的水性残余物低压冻干,得到终产物。将通过制备型HPLC纯化的产物分离为游离碱、甲酸盐/酯或TFA盐/酯,除非另有说明。
使用的液相色谱法质谱法(LCMS)和HPLC系统为:
方法1
具有C18-反相柱(30×4.6mmPhenomenexLuna3μm粒度)的WatersPlatformLCQuadrupole质谱仪,洗脱使用A:水+0.1%甲酸;B:乙腈+0.1%甲酸。梯度:
检测-MS、ELS、UV(200μL分流至具有在线(in-line)HP1100DAD检测器的MS)。MS电离方法-电喷射(正离子和负离子)。
方法2
具有C18-反相柱(30×4.6mmPhenomenexLuna3μm粒度)的WatersZMD四极质谱仪,洗脱使用A:水+0.1%甲酸;B:乙腈+0.1%甲酸。梯度:
检测-MS、ELS、UV(200μL分流至具有在线Waters996DAD检测器的MS)。MS电离方法-电喷射(正离子和负离子)。
方法3
具有C18-反相柱(30×4.6mmPhenomenexLuna3μm粒度)的WatersZMD四极质谱仪,洗脱使用A:水+0.1%甲酸;B:乙腈+0.1%甲酸。梯度:
检测-MS、ELS、UV(200μL分流至具有在线HP1100DAD检测器的MS)。MS电离方法-电喷射(正离子和负离子)。
方法4
具有C18-反相柱(30×4.6mmPhenomenexLuna3μm粒度的VGPlatformII四极波谱仪,洗脱使用A:水+0.1%甲酸;B:乙腈+0.1%甲酸。梯度:
检测-MS、ELS、UV(200μl/min分流至具有在线HP1050DAD检测器的ESI源)。MS电离方法-电喷射(正离子和负离子)。
方法5
具有维持在40℃的AcquityBEHC181.7um100×2.1mm、AcquityBEHShieldRP181.7um100×2.1mm或AcquityHSST31.8um100x2.1mm的Waters微质量ZQ2000四极质谱仪。洗脱使用A:水+0.1%甲酸;B:乙腈+0.1%甲酸。梯度:
检测-MS、UVPDA。MS电离方法-电喷射(正离子和负离子)。
方法6
PhenomenexGeminiC18-反相柱(250×21.20mm5μm粒度),洗脱使用A:水+0.1%甲酸;B:CH3CN+0.1%甲酸。梯度–历时20min从90%A/10%B至2%A/98%B-流速18mL/min。检测–设定在254nM波长的在线紫外检测器。
实施例1
1-(5-叔丁基-2-苯基-2H-吡唑-3-基)-3-[(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲
a.2,2,2-三氟-N-(S)-1,2,3,4-四氢-萘-1-基-乙酰胺(中间体1a)
将三氟乙酸乙酯(24.2mL,204mmol)逐滴加入到(S)-(1,2,3,4-四氢-萘-1-基)胺(AlfaAesar)(25.0g,170mmol)和三乙胺(35.5mL,255mmol)在甲醇(250mL)中的搅拌溶液中,并将反应物搅拌18h。将混合物浓缩至它的体积的大约1/3,然后在DCM(200mL)和水(200mL)之间分配。将水层萃取进DCM(3×)中,并将合并的有机层用盐水洗涤、干燥(MgSO4)和在真空中浓缩,得到标题化合物(41.1g,169mmol,99%)。1HNMR(400MHz,CDCl3):1.80-1.95(3H,m),2.05-2.15(1H,m),2.75-2.90(2H,m),5.18-5.25(1H,q,J5.0Hz),6.38-6.48(1H,brs),7.12-7.16(1H,m),7.20-7.26(3H,m)。
b.2,2,2-三氟-N-((S)-4-氧代-1,2,3,4-四氢-萘-1-基)-乙酰胺(中间体1b)
将在水(500mL)中的一水合硫酸镁(46.6g,338mmol)加入到冰冷的中间体1a(41.1g,169mmol)在丙酮(1.0L)中的溶液中。在45min时段内逐份加入(10.0g份)高锰酸钾(80.1g,507mmol)。然后将混合物搅拌18h。加入在水(400mL)中的五水合硫代硫酸钠(126g,510mmol),并将反应物搅拌30min。将混合物浓缩至~300mL,然后顺序地加入水(1.0L)、硅藻土(Celite)(60g)和EtOAc(1.0L)。将混合物彻底搅拌,然后穿过硅藻土(Celite)垫过滤。将水层萃取进EtOAc(3×)中,并将合并的有机层用盐水洗涤、干燥(MgSO4)和在真空中浓缩,得到标题化合物(36.6g,142mmol,84%)。1HNMR(400MHz,CDCl3):2.20-2.30(1H,dddd,J13.3,10.0,8.8,4.5Hz),2.43-2.52(1H,dddd,J13.3,7.2,4.6,4.6Hz),2.67-2.77(1H,ddd,J17.4,10.1,4.6Hz),2.78-2.88(1H,ddd,J17.4,7.1,4.6Hz),5.39-5.47(1H,td,8.5,4.5Hz),7.32-7.37(1H,d,J7.7Hz),7.44-7.49(1H,t,J7.6Hz),7.59-7.64(1H,td,J7.6,1.4Hz),8.03-8.07(1H,dd,J7.7,1.4Hz)。
c.2,2,2-三氟-N-((1S,4R)-4-羟基-1,2,3,4-四氢-萘-1-基)-乙酰胺(中间体1c)
将脱气的DMF(用氩气鼓泡,100mL)加入到中间体1b(8.00g,31.3mmol)和[N-[(1R,2R)-2-(氨基-κN)-1,2-二苯基乙基]-4-甲基苯磺酰胺合(sulfonamidato)-κN]氯[(1,2,3,4,5,6-η)-1-甲基-4-(1-甲基乙基)苯]-钌(StremChemicalsInc.:594mg,0.93mmol)中。将三乙胺(8.66mL,62.6mmol)缓慢地加入到冰冷的甲酸(2.34mL,62.6mmol)中并搅拌20min,然后将其加入到DMF溶液中。将反应物加热至60℃保持18h。冷却后,将混合物在DCM(200mL)和水(600mL)之间分配。用DCM(3×)萃取水层,并将合并的有机层用盐水洗涤、干燥(MgSO4)和在真空中浓缩,然后使用0-100%的EtOAc在环己烷中的溶液通过FCC进行纯化,得到标题化合物(7.10g,27.4mmol,88%)。1HNMR(400MHz,CDCl3):1.88-1.92(1H,d,J4.8Hz),1.98-2.18(4H,m),4.80-4.88(1H,m),5.165-5.24(1H,m),6.70-6.80(1H,brs),7.25-7.30(1H,m),7.30-7.40(2H,m),7.45-7.50(1H,m)。
d.(1R,4S)-4-氨基-1,2,3,4-四氢-萘-1-酚(中间体1d)
将氢氧化钠(2.10g,53.0mmol)加入到冰冷的中间体1c(3.43g,13.2mmol)在甲醇/水(2:1,50mL)中的溶液中。将反应物搅拌3.5h,然后穿过SCX-2柱,用MeOH洗涤,并用2M的NH3在MeOH中的溶液洗脱,得到标题化合物(2.30g,13.2mmol,99%)。1HNMR(400MHz,d6-DMSO):1.66-1.90(4H,m),3.71-3.77(1H,t,J5.4Hz),4.46-4.54(1H,t,J5.4Hz),7.14-7.22(2H,m),7.32-7.38(1H,m),7.40-7.46(1H,m)。
e.异丁酸N'-(5-氟-吡啶-2-基)-酰肼(中间体1e)
向5-氟-2-肼基-吡啶(根据在WO2010022076中描述的操作制备;2.08g,16.4mmol)、异丁酸(1.82mL,19.6mmol)、和HOBt水合物(251mg,1.64mmol)在DCM(50mL)中的溶液中,加入EDC(3.76g,19.6mmol),并将得到的橙色溶液在室温搅拌18h。加入饱和NaHCO3水溶液(50mL),并将混合物剧烈搅拌15min。将有机物用饱和NaHCO3水溶液(50mL)洗涤,穿过疏水玻璃料,并在真空下浓缩,剩下淡棕色固体。将固体悬浮于Et2O(50mL)中并过滤,用Et2O(25mL)洗涤,剩下白色固体(1.48g,46%)。将醚洗液在真空下浓缩,并将残余物悬浮于Et2O(10mL)中,过滤,用Et2O(2×2mL)洗涤,剩下白色固体(330mg,10%)。合并固体(1.81g,56%)。1HNMR(400MHz,CDCl3):1.23(6H,d),2.50(1H,七重峰(sept)),6.65(1H,dd),6.80(1H,d),7.29(1H,ddd),7.77(1H,brs),8.01(1H,d)。
f.6-氟-3-异丙基-[1,2,4]三唑并[4,3-a]吡啶(中间体1f)
在0℃,向中间体1e(1.81g,9.18mmol)、三苯基膦(4.83g,18.4mmol)和三乙胺(5.12mL,36.7mmol)在THF(25mL)中的溶液中,以1min间隔加入分成2份的六氯乙烷(4.36g,18.4mmol)。将得到的淡棕色溶液温热至室温,然后搅拌2h。将得到的黄色混悬液过滤,用THF(2×25mL)洗涤。将合并的有机物使用SCX-2柱纯化(用DCM-MeOH(1:1,100mL)和MeOH(50mL)洗涤,然后用2M的NH3在MeOH中的溶液洗脱产物),得到淡黄色固体(1.60g,97%,被~2.5%Ph3P=O污染)。1HNMR(400MHz,CDCl3):1.53(6H,d),3.32(1H,七重峰),7.15(1H,ddd),7.75(1H,ddd),7.84(1H,m)。
g.(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基胺(中间体1g)
将中间体1d(634mg,3.88mmol)逐份加入到氢化钠(60%的在矿物油中的溶液,466mg,11.65mmol)在无水DMF(5mL)中的混悬液中,并将混合物在室温搅拌20min。然后逐份加入中间体1f(535mg,2.99mmol),并将混合物在60℃加热4h。将反应物冷却,用水淬灭,并用EtOAc(3×)萃取。将合并的有机萃取物用盐水洗涤和干燥(Na2SO4),蒸发并通过SCX-2纯化,先后用MeOH和2M的NH3在MeOH中的溶液洗脱,得到标题化合物(274mg,79%)。LCMS(方法1):Rt1.76min,m/z180[MH+]。
h.1-(5-叔丁基-2-苯基-2H-吡唑-3-基)-3-[(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲(实施例1)
将中间体1g(100mg,0.31mmol)在含有EtNiPr2(81.0μL,0.46mmol)和(5-叔丁基-2-苯基-2H-吡唑-3-基)-氨基甲酸-2,2,2-三氯-乙酯(关于参考操作,参见WO2008016192;185mg,0.46mmol)的二噁烷(5mL)中的溶液在60℃加热2h。冷却后,通过SCX-2(先后用MeOH和2M的NH3在MeOH中的溶液洗脱)和随后的HPLC(用55-98%的H2O在MeCN(0.1%NH3)中的溶液洗脱)纯化溶液,得到作为无色粉末的标题化合物(120mg,69%)。LCMS(方法5):Rt4.47分钟,m/z=564.2[MH+]。1HNMR(400MHz,CDCl3):1.32(9H,s),1.43-1.45(3H,d,J6.8Hz),1.47-1.50(3H,d,J6.8Hz),1.88-1.96(1H,m),2.00-2.16(2H,m),2.20-2.28(1H,m),3.16-3.30(1H,sp,J6.9Hz),5.04-5.16(1H,m),5.16-5.21(1H,t,J3.8Hz),5.38-5.46(1H,d,J8.8Hz),6.30(1H,s),6.51(1H,s),7.00-7.06(1H,dd,J9.9,2.1Hz),7.22-7.34(5H,m),7.38-7.46(3H,m),7.52-7.62(3Hm)。
实施例2
1-环丙基-3-[(1S,4S)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲
a.2,2,2-三氟-N-((1S,4S)-4-羟基-1,2,3,4-四氢-萘-1-基)-乙酰胺(中间体2a)
用氩气在中间体1b(8.00g,31.1mmol)和[N-[(1S,2S)-2-(氨基-κN)-1,2-二苯基乙基]-4-甲基苯磺酰胺合-κN]氯[(1,2,3,4,5,6-η)-1-甲基-4-(1-甲基乙基)苯]-钌(StremChemicalsInc.;0.06g,0.93mmol)于无水DMF(100mL)中的溶液中鼓泡10min。加入甲酸(2.4mL,62.2mmol)和Et3N(8.60mL,62.2mmol)的预混合组合,并将混合物在50℃搅拌24h。将混合物冷却至室温,并浓缩至~25mL。加入水(70mL),将得到的沉淀物过滤,并用DCM(3×30mL)和乙醚(30mL)洗涤,剩下固体(4.75g)。倾析滤液,剩下深色固体。随后使用0-30%的EtOAc在环己烷中的溶液通过FCC进行纯化,得到固体。将其与首先得到的固体组合,得到米色固体(5.93g,74%)。1HNMR(400MHz,d6-DMSO):1.60-1.83(2H,m),2.06-2.17(2H,m),4.60(1H,m),5.08(1H,m),5.28(1H,d),7.07(1H,m),7.25(1H,ddd),7.28(1H,ddd),7.50(1H,dd),9.78(1H,d)。
b.(1S,4S)-4-氨基-1,2,3,4-四氢-萘-1-酚(中间体2b)
向中间体2a(5.55g,21.4mmol)在MeOH(50mL)中的灰色溶液中,加入NaOH(1.28g,32.1mmol)在水(15mL)中的溶液,并将混合物在室温搅拌3天。加入NaOH(1.28g,32.1mmol),并将棕色溶液搅拌5h。将溶液直接应用于SCX-2柱,用MeOH洗涤,并用2M的NH3在MeOH中的溶液洗脱,并在真空下浓缩,剩下灰色固体。利用声处理将固体悬浮于DCM(50mL)中,然后过滤和在真空下干燥,剩下淡灰色固体(2.93g,84%)。1HNMR(400MHz,d6-DMSO):1.41-1.64(2H,m),2.02-2.13(2H,m),3.82(1H,dd),4.55(1H,dd),5.08(1H,brs),7.13-7.22(2H,m),7.35-7.49(2H,m)。
c.(1S,4S)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基胺(中间体2c)
在室温,在氮气下,向氢化钠(60%的在矿物油中的溶液,1.07g,26.8mmol)在无水DMF(20mL)中的混悬液中,历时2min逐份加入中间体2b(1.89g,11.6mmol),并将得到的棕色溶液搅拌20min。加入中间体1f(1.60g,8.93mmol),并将溶液在60℃搅拌2h。将深棕色溶液冷却至室温,并在真空下浓缩。将残余物通过SCX-2进行纯化,用MeOH(200mL)洗涤,并用2M的NH3在MeOH中的溶液洗脱,剩下深棕色泡沫(3.21g)。使用2-10%[2M的NH3在MeOH中的溶液]在DCM中的溶液,通过FCC进一步纯化,得到棕色泡沫(2.11g,76%)。1HNMR(400MHz,d6-DMSO):1.37(3H,d),1.39(3H,d),1.59(1H,m),1.91(1H,m),2.11(1H,m),2.33(1H,m),3.58(1H,七重峰),3.96(1H,dd),5.55(1H,dd),7.18-7.37(4H,m),7.51(1H,d),7.68(1H,d),8.20(1H,d)。
d.1-环丙基-3-[(1S,4S)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲(实施例2)
向中间体2c(93.5mg,0.29mmol)和DIPEA(63μL,0.363mmol)在THF(4mL)中的混浊橙色溶液中,加入环丙基-氨基甲酸-4-硝基-苯酯(关于参考操作,参见WO2007/72158;77.4mg,0.348mmol)。将得到的澄清橙色溶液在室温搅拌10min,然后在80℃搅拌3h。冷却后,将混合物在真空下浓缩,剩下棕色残余物。通过FCC(5-20%的MeOH在EtOAc中的溶液)进行纯化,得到棕色玻璃,将其研磨(乙醚),剩下淡黄色固体(64.7mg,55%)。通过HPLC(10-95%的MeCN在水中的溶液,0.1%HCO2H)进一步纯化,得到淡黄色固体(42.2mg,30%)。LCMS(方法5):Rt3.13分钟,m/z406[MH+]。1HNMR(400MHz,CDCl3):0.34(2H,m),0.57(2H,m),1.37(3H,d),1.39(3H,d),1.74(1H,m),1.97(1H,m),2.10(1H,m),2.22(1H,m),2.47(1H,m),3.57(1H,七重峰),4.90(1H,m),5.57(1H,dd),6.05(1H,d),6.18(1H,d),7.23(1H,dd),7.25-7.37(3H,m),7.39(1H,d),7.68(1H,d),8.21(1H,d)。
实施例3
(±)-反式-1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[3-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基硫烷基)-茚满-1-基]-脲
a.(±)-3-叔丁基硫烷基-茚满-1-酮(中间体3a)
在0℃,向3-溴-茚满-1-酮(6.6g,31mmol)在THF(25mL)中的溶液中,加入叔丁烷硫醇(7.0mL,62mmol),随后加入DIPEA(逐滴加入;10.6mL,62mmol)。将混合物在0℃搅拌45min,然后将其温热至室温保持1h,然后在50℃加热90min。将混合物浓缩并与甲苯共沸,在Et2O/水之间分配,并用Et2O萃取。将合并的有机萃取物干燥(Na2SO4)和蒸发。使用0-16%的EtOAc在环己烷中的溶液作为洗脱液,通过FCC进行纯化,得到作为淡黄色固体的标题化合物(3.6g)。1HNMR(400MHz,CDCl3):1.47(9H,s),2.86(1H,dd,J3.419.0Hz),3.28(1H,dd,J3.3,19.0Hz),4.46-4.52(1H,m),7.38-7.46(1H,m),7.61-7.67(1H,m),7.69-7.75(2H,m)。
b.(±)-顺式-3-叔丁基硫烷基-茚满-1-酚(中间体3b)
形成中间体3a(3.5g,15.9mmol)在MeOH(90mL)中的溶液,并冷却至0℃。加入硼氢化钠(608mg,16mmol),并将混合物在0℃搅拌40分钟。通过加入AcOH(2mL)来淬灭反应,然后蒸发,得到白色固体。将残余物在EtOAc和饱和NaHCO3溶液(水)之间分配,然后用EtOAc萃取。将合并的有机物干燥(Na2SO4),过滤,蒸发,然后使用6-30%的EtOAc在环己烷中的溶液作为洗脱液通过FCC进行纯化,得到作为白色固体的标题化合物(2.9g)。1HNMR(400MHz,CDCl3):1.46(9H,s),2.10-2.19(1H,m),2.97-3.07(1H,m),4.14-4.21(1H,m),5.11-5.17(1H,m),7.27-7.36(2H,m),7.41-7.48(2H,m)。
c.(±)-反式-2-(3-叔丁基硫烷基-茚满-1-基)-异吲哚-1,3-二酮(中间体3c)
在0℃,搅拌中间体3b(2.9g,13.1mmol)、邻苯二甲酰亚胺(2.3g,15.7mmol)和三苯基膦(4.1g,15.7mmol)在THF(100mL)中的溶液。逐滴加入DIAD(3.08mL,15.7mmol),并将混合物温热至室温过夜。加入水(10滴),然后蒸发至干燥。使用0-12%的EtOAc在环己烷中的溶液作为洗脱液,通过FCC进行纯化,得到作为灰白色固体的标题化合物(2.98g).)。LCMS(方法2):Rt4.45min,m/z262[(M-StBu)+]。
d.(±)-反式-2-[3-(2-硝基-苯基二硫烷基)-茚满-1-基]-异吲哚-1,3-二酮(中间体3d)
向中间体3c(600mg,1.71mmol)在AcOH(3mL)中的混悬液中,加入2-硝基苯次磺酰氯(2-nitrobenzenesulfenylchloride)(342mg,1.8mmol),得到深黄色溶液。在室温搅拌30分钟以后,将得到的沉淀物过滤,并用1:1Et2O/环己烷、然后用环己烷洗涤,并在真空下干燥,得到作为灰白色固体的含有1当量AcOH的标题化合物(355mg)。1HNMR(400MHz,CDCl3):2.61-2.70(1H,m),2.96-3.06(1H,m),4.86-4.90(1H,m),6.06(1H,t,J7.7Hz),7.03-7.08(1H,m),7.17-7.23(2H,m),7.29-7.26(1H,m),7.41-7.45(1H,m),7.61-7.67(1H,m),7.69-7.74(2H,m),7.78-7.84(2H,m),8.19-8.27(2H,m)。
e.(±)-反式-2-(3-巯基-茚满-1-基)-异吲哚-1,3-二酮(中间体3e)
向中间体3d(396mg,0.78mmol)在MeOH(16mL)中的混悬液中,加入碳酸钾(400mg,2.3mmol)和二硫苏糖醇(160mg,1.0mmol)。将混合物在室温搅拌30分钟。加入KH2PO4(800mg),随后加入AcOH(30滴)。将混合物在EtOAc/水之间分配,用EtOAc萃取,并将合并的有机物干燥(Na2SO4)和蒸发。使用3-5%的EtOAc在环己烷中的溶液作为洗脱液,通过FCC进行纯化,得到作为黄色胶状物的标题化合物(158mg)。1HNMR(400MHz,CDCl3):2.45-2.55(1H,m),3.00-3.09(1H,m),4.90-4.98(1H,m),6.00-6.05(1H,m),7.10-7.14(1H,m),7.18-7.24(1H,m),7.30-7.36(1H,m),7.45-7.48(1H,m),7.68-7.75(2H,m),7.78-7.84(2H,m)。
f.(±)-反式-2-[3-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基硫烷基)-茚满-1-基]-异吲哚-1,3-二酮(中间体3f)
将中间体3e(104mg,0.35mmol)和6-碘-3-异丙基-[1,2,4]三唑并[4,3-a]吡啶(关于参考操作,参见WO2010094956;101mg,0.35mmol)在无水DMF(1mL)中的溶液用氩气脱气。加入Cs2CO3(172mg,0.53mmol)和Pd(dppf)Cl2.DCM(57mg,0.07mmol),并将混合物加热至90℃过夜。将混合物蒸发至干燥,在DCM/水之间分配,并用DCM萃取。将合并的有机物干燥(Na2SO4),过滤,蒸发,然后使用0-8%的MeOH在DCM中的溶液作为洗脱液,通过FCC进行纯化。使用10-80%EtOAc的DCM作为洗脱液,通过FCC再纯化残余物,得到标题化合物(37mg)。LCMS(方法2):Rt3.45min,m/z455[MH+]。
g.(±)-反式-3-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基硫烷基)-茚满-1-基胺(中间体3g)
形成中间体3f(37mg,0.08mmol)在MeOH(10mL)中的溶液。加入一水合肼(250μL),并将混合物在室温搅拌过夜。蒸发至干燥,并使用0-6%(9:1MeOH/NH3水)在DCM中的溶液作为洗脱液,通过FCC进行纯化,得到标题化合物(15mg)。LCMS(方法1):Rt1.94min,m/z325[MH+]。
h.(±)-反式-1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[3-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基硫烷基)-茚满-1-基]-脲(实施例3)
用与在实施例1步骤h中描述的操作类似的操作,使用中间体3g和(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-氨基甲酸-2,2,2-三氯-乙酯(SyntheticCommunications,39(22),3999-4009;2009),制备标题化合物。LCMS(方法5):Rt4.94min,m/z580[MH+]。1HNMR(300MHz,CDCl3):1.30(9H,s),1.43(6H,dd,J10.3,6.9Hz),2.12-2.22(1H,m),2.36(3H,s),2.63-2.71(1H,m),3.17-3.26(1H,m),4.61-4.65(1H,m),5.15(1H,d,J8.2Hz),5.43-5.51(1H,m),6.22(1H,s),6.31(1H,s),6.99(1H,d,J6.9Hz),7.09(1H,d,J7.1Hz),7.15-7.27(5H,m),7.33-7.37(2H,m),5.57-7.61(1H,m),7.75(1H,m)。
实施例4
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[(1S,4R)-4-{3-[3-(2-吗啉-4-基-乙氧基)-苯基]-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基}-1,2,3,4-四氢-萘-1-基)-脲
a.N-(5-氟-吡啶-2-基)-N’-[1-[3-(2-吗啉-4-基-乙氧基)-苯基]-次甲基(methylidine)]-肼(中间体4a)
将5-氟-2-肼基-吡啶(关于参考操作,参见WO2010022076;9.2g,0.072mol)加入到3-(2-吗啉-4-基-乙氧基-苯甲醛(关于参考操作,参见WO2628448;17.0g,0.073mol)在乙醇(175mL)中的溶液中,并将混合物搅拌1h。将得到的沉淀物滤出,得到作为米色固体的标题化合物(19.46g,79%)LCMS(方法2):Rt2.33min,m/z345[MH+]。
b.6-氟-3-[3-(2-吗啉-4-基-乙氧基)-苯基]-[1,2,4]三唑并[4,3-a]吡啶(中间体4b)
将乙醇(10mL)加入到中间体4a和(二乙酰氧基碘)苯(7.9g,0.024mol)在二氯甲烷(60mL)中的溶液中,并将混合物在室温搅拌3h。蒸发溶剂,并使用0-20%的MeOH在DCM中的溶液,通过FCC纯化残余物,得到棕色油。将其溶解在二氯甲烷中,并用NaHCO3洗涤,干燥(MgSO4)和蒸发,得到作为米色固体的标题化合物(4.1g,69%)。LCMS(方法2):Rt0.28min,m/z343[MH+]。
c.(1S,4R)-4-{3-[3-(2-吗啉-4-基-乙氧基)-苯基]-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基}-1,2,3,4-四氢-萘-1-基胺(中间体4c)
用与在实施例1步骤g中描述的操作类似的操作,从中间体4b和中间体1d开始,制备标题化合物。LCMS(方法1):Rt1.68min,m/z486[MH+]。
d.1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-((1S,4R)-4-{3-[3-(2-吗啉-4-基-乙氧基)-苯基]-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基}-1,2,3,4-四氢-萘-1-基]-脲(实施例4)
用与在实施例1步骤h中描述的操作类似的操作,从中间体4c和(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-氨基甲酸-2,2,2-三氯-乙酯(SyntheticCommunications,39(22),3999-4009;2009)开始,制备标题化合物。LCMS(方法5):Rt3.94min,m/z741[MH+]。1HNMR(400MHz,CDCl3):1.32(9H,s),1.84-1.94(1H,m),1.98-2.09(2H,m),2.17-2.24(1H,m),2.36(3H,s),2.56(4H,m),2.83(2H,t,J5.62Hz),3.68(4H,t,J4.59Hz),4.18(2H,t,J5.63Hz),5.03-5.09(1H,m),5.17-5.22(2H,m),6.27(2H,s),7.07(1H,dd,J2.518.32Hz),7.13(1H,ddJ2.15,9.92,Hz),7.21-7.39(11H,m),7.46(1H,t),7.74(1H,d,J10.09Hz),7.87(1H,s)。
实施例5
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-7-基氧基)-1,2,3,4-四氢-萘-1-基]-脲
a.(1S,4R)-4-(2-氟-吡啶-4-基氧基)-1,2,3,4-四氢-萘-1-基胺(中间体5a)
形成中间体1d(400mg,2.45mmol)在THF(10mL)中的溶液。加入氢化钠(60%的在矿物油中的溶液,118mg,2.94mmol),并将混合物在室温搅拌15分钟。加入2,4-二氟吡啶(338mg,2.94mmol)在THF(1mL)中的溶液,并将混合物在室温搅拌2h。加入其它氢化钠(60%的在矿物油中的溶液,100mg,2.5mmol),并将混合物在室温搅拌1h。将反应混合物小心地用水淬灭,然后在水和EtOAc之间分配。用EtOAc萃取水层,并将合并的有机相干燥(硫酸钠)、过滤和蒸发。使用0-10%的MeOH在DCM中的溶液作为洗脱液,通过FCC进行纯化,得到作为棕色油的粗制标题化合物(500mg)。LCMS(方法1):Rt0.32,1.83,2.05min,m/z259[MH+]。
b.[(1S,4R)-4-(2-氟-吡啶-4-基氧基)-1,2,3,4-四氢-萘-1-基]-氨基甲酸叔丁酯(中间体5b)
形成中间体5a(500mg,1.9mmol)在DCM(20mL)中的溶液。加入三乙胺(290μL,2.1mmol),随后加入Boc-酸酐(465mg,2.1mmol),并将混合物在室温搅拌4h。将混合物在DCM/水之间分配,并穿过Isolute相分离柱分离各相。将有机相蒸发,然后使用0-50%EtOAc/c-己烷作为洗脱液,通过FCC进行纯化,得到作为棕色油的粗制标题化合物(300mg)。LCMS(方法1):Rt3.83min,m/z359[MH+]。
c.[(1S,4R)-4-(2-肼基-吡啶-4-基氧基)-1,2,3,4-四氢-萘-1-基]-氨基甲酸叔丁酯(中间体5c)
形成中间体5b(300mg,0.84mmol)在IMS(5mL)中的溶液。加入一水合肼(5mL),并将混合物在密闭试管中在80℃加热过夜。将混合物浓缩,并在EtOAc/水之间分配,用EtOAc萃取,并将合并的有机物干燥(Na2SO4)、过滤和蒸发,得到作为黄色泡沫的粗制标题物质(300mg)。LCMS(方法4):Rt2.17min,m/z371[MH+]。
d.{(1S,4R)-4-[2-(N'-异丁酰基-肼基)-吡啶-4-基氧基]-1,2,3,4-四氢-萘-1-基}-氨基甲酸叔丁酯(中间体5d)
形成中间体5c(300mg,0.81mmol)在DCM(10mL)中的溶液。加入三乙胺(170μL,1.20mmol)和异丁酰氯(102μL,0.97mmol),并将混合物在室温搅拌2h。在DCM/水之间分配,使用相分离柱分离并蒸发。使用0-100%的EtOAc在环己烷中的溶液作为洗脱液,通过FCC进行纯化,得到作为黄色固体的粗制标题化合物(150mg)。LCMS(方法1):Rt2.49min,m/z441[MH+]。
e.[(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-7-基氧基)-1,2,3,4-四氢-萘-1-基]-氨基甲酸叔丁酯(中间体5e)
形成中间体5d(150mg,0.34mmol)在THF(10mL)中的溶液。加入三乙胺(188μL,1.36mmol)和三苯基膦(179mg,0.68mmol),并将混合物在冰浴中冷却。加入六氯乙烷(160mg,0.68mmol),并将混合物在0℃搅拌10min,然后将其温热至室温过夜。加入额外的三乙胺(188μL,1.36mmol)、三苯基膦(179mg,0.68mmol)和六氯乙烷(160mg,0.68mmol),并将混合物在50℃加热1h。冷却后,将混合物在EtOAc/水之间分配,然后用EtOAc萃取。将合并的有机物干燥(Na2SO4)、过滤和蒸发,然后使用0-10%的MeOH在EtOAc中的溶液作为洗脱液,通过FCC进行纯化,得到作为灰白色固体的标题物质(110mg)。LCMS(方法1):Rt2.79min,m/z423[MH+]。
f.(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-7-基氧基)-1,2,3,4-四氢-萘-1-基胺(中间体5f)
形成中间体5e(110mg,0.26mmol)在DCM(6mL)中的溶液。加入TFA(3mL),并将混合物在室温搅拌1h。使用SCX-2柱进行纯化,用MeOH洗涤,然后用2M的NH3在MeOH中的溶液洗脱,得到作为棕色泡沫的粗制标题化合物(80mg)。LCMS(方法1):Rt0.31,1.55min,m/z323[MH+]。
g.1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-7-基氧基)-1,2,3,4-四氢-萘-1-基]-脲(实施例5)
用与在实施例1步骤h中描述的操作类似的操作,从中间体5f和(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-氨基甲酸-2,2,2-三氯-乙酯(SyntheticCommunications,39(22),3999-4009;2009)开始,制备标题化合物。LCMS(方法5):Rt4.27min,m/z578[MH+]。1HNMR(400MHz,d6-DMSO):1.27(9H,s),1.36(6H,dd,J2.57.0Hz),1.77-1.86(1H,m),1.93-2.01(1H,m),2.03-2.17(2H,m),2.36(3H,s),3.43-3.53(1H,m),4.79-4.85(1H,m),5.69(1H,t,J4.5Hz),6.33(1H,s),6.63(1H,dd,J2.5,7.4Hz),7.10(1H,d,J8.7Hz),7.27-7.38(9H,m),8.03(1H,s),8.34(1H,d,J7.4Hz)。
实施例6
1-{5-叔丁基-2-[3-(2-吗啉-4-基-乙氧基)-苯基]-2H-吡唑-3-基}-3-[(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲
a.5-叔丁基-2-[3-(2-吗啉-4-基-乙氧基)-苯基]-2H-吡唑-3-基胺(中间体6a)
将DIAD(847μL,4.32mmol)缓慢地加入到3-(5-氨基-3-叔丁基-1H-吡唑-1-基)苯酚(关于参考操作,参见US2006/35922;500mg,2.16mmol)、4-(2-羟乙基)吗啉(394μl,3.25mmol)和三苯基膦(1.13g,4.32mmol)在THF(10.0mL)中的溶液中,并搅拌72h。将反应混合物在EtOAc(75mL)和H2O(75mL)之间分配,并用EtOAc(3×)萃取水层。将合并的有机层干燥(MgSO4)、过滤和在真空中蒸发,并使用0.5-6%[2M的NH3在MeOH中的溶液]在DCM中的溶液,通过FCC进行纯化,得到半纯标题化合物(526mg)。将其不经进一步纯化进入下一反应。LCMS(方法4):Rt0.28min,m/z345[MH+]。
b.{5-叔丁基-2-[3-(2-吗啉-4-基-乙氧基)-苯基]-2H-吡唑-3-基}-氨基甲酸-2,2,2-三氯-乙酯(中间体6b)
将中间体6a(75.0mg,0.22mmol)溶解在THF(2.0mL)中,并在冰/水浴中冷却。加入二异丙基乙胺(76μL,0.44mmol),随后加入氯甲酸-2,2,2-三氯乙酯(30μL,0.22mmol)。30分钟以后,除去冰浴,并将反应物温热至室温过夜。将反应混合物在EtOAc(50mL)和H2O(50mL)之间分配,并用EtOAc(3×)萃取水层。将合并的有机层干燥(MgSO4)、过滤和在真空中蒸发,得到标题化合物(115mg,0.22mmol,99%)。LCMS(方法4):Rt2.53min,m/z521[MH+]。
c.1-{5-叔丁基-2-[3-(2-吗啉-4-基-乙氧基)-苯基]-2H-吡唑-3-基}-3-[(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲(实施例6)
用与在实施例1步骤h中描述的操作类似的操作,从中间体6b和中间体1g开始,制备标题化合物。LCMS(方法5):Rt3.41min,m/z=693[MH+]。1HNMR(400MHz,CDCl3):1.30(9H,s),1.41-1.45(3H,d,J6.9Hz),1.45-1.48(3H,d,J6.9Hz),1.88-1.98(1H,m),2.00-2.12(2H,m),2.18-2.28(1H,m),2.52-2.58(4H,t,J4.6Hz),2.76-2.82(2H,t,J5.6Hz),3.17-3.28(1H,sp,J6.9Hz),3.64-3.68(4H,t,J4.7Hz),4.10-4.14(2H,t,J5.5Hz),5.03-5.10(1H,td,J9.0,5.4Hz),5.14-5.18(1H,t,J7.9),5.52-5.58(1H,brd,J8.7Hz),6.30(1H,s),6.63(1H,s),6.82-6.86(1H,dd,J8.5,2.5Hz),6.99-7.03(1H,dd,J9.9,2.0Hz),7.05-7.07(1H,t,J2.1Hz),7.07-7.10(1H,d,J7.8Hz),7.23-7.31(5H,m),7.40-7.42(1H,d,J1.8Hz),7.56-7.60(1H,d,J9.8Hz)。
实施例7
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-{(1S,4R)-4-(3-(2-羟基-苯基)-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基}-脲
在室温在氢气下,将实施例24(150mg,0.21mmol)在乙醇(5mL)中的溶液在氢氧化钯(20%在炭上;50mg)上面氢解过夜。穿过硅藻土(Celite)滤出催化剂,并蒸发滤液。通过HPLC(方法6)纯化残余物。将含有产物的级分冷冻干燥,得到作为无色固体的标题化合物。LCMS(方法5):Rt4.77min,m/z628[MH+]。1HNMR(400MHz,CDCl3):1.32(9H,s),1.85-1.94(1H,m),2.02-2.11(2H,m),2.23-2.30(1H,m),2.36(3H,s),5.04-5.12(2H,m),5.25(1H,m),6.18(1H,brs),6.25(1H,s),7.00-7.04(1H,m),7.17-7.26(6H,m),7.29-7.33(3H,m),7.36-7.40(3H,m),7.59(1H,dd,J1.72,7.80Hz),7.77(1H,d,J9.92Hz),8.09(1H,d,J1.45,Hz)。
实施例8
1-(5-叔丁基-异噁唑-3-基)-3-[(1S,3S)-3-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-茚满-1-基]-脲
用与在实施例1、步骤g和h和实施例6步骤b中描述的操作类似的操作,从(1S,3S)-3-氨基-茚满-1-酚(ChemistryLetters,2002,3,266-267)和5-叔丁基-异噁唑-3-基胺(AlfaAesar)开始,制备标题化合物。LCMS(方法5):Rt4.23min,m/z578[MH+]。1HNMR(400MHz,CDCl3):1.28(9H,s),1.48(6H,dd,J9.62和6.89Hz),2.35(1H,m),2.89(1H,m),3.26(1H,m),5.68-5.76(3H,m),7.05(1H,dd,J9.87和2.06),7.29-7.34(2H,m),7.35-7.41(2H,m),7.48(1H,m),7.68(2H,m),7.76(1H,m)。
实施例9
N-(4-{(1R,4S)-4-[3-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-脲基]-1,2,3,4-四氢-萘-1-基氧基甲基}-吡啶-2-基)-2-甲氧基-乙酰胺
a.((1S,4R)-4-羟基-1,2,3,4-四氢-萘-1-基)-氨基甲酸叔丁酯(中间体9a)
将中间体1d(1.35g,8.28mmol)悬浮于乙腈(40mL)中,然后加入二碳酸二叔丁酯(1.99g,9.11mmol)。将混合物在室温搅拌22h,然后蒸发至干燥。通过FCC进行纯化,用0-75%乙酸乙酯在环己烷中的溶液洗脱,得到作为白色泡沫的标题化合物(2.12g,97%)。LCMS(方法3):Rt3.31min,m/z286[MNa+]。
b.[(1S,4R)-4-(2-氨基-吡啶-4-基甲氧基)-1,2,3,4-四氢-萘-1-基]-氨基甲酸叔丁酯(中间体9b)
在氩气下,将中间体9a(1.47g,5.59mmol)溶解在无水DMF(15mL)中,并在冰浴中冷却。向其中加入氢化钠(60%的在矿物油中的溶液,224mg,5.59mmol)并搅拌10min。加入额外的氢化钠(60%的在矿物油中的溶液,224mg,5.59mmol),随后立即加入2-氨基-4-溴甲基吡啶氢溴酸盐(关于参考操作,参见Bioorg.Med.Chem.Letts,2011,21,4,1232)(1.50g,5.59mmol)。将混合物在氩气下在冷却下搅拌1h。将反应混合物用水稀释,并用DCM(4×30mL)萃取。将合并的有机层用盐水洗涤,干燥(Na2SO4)和蒸发。通过FCC纯化残余物,用0-10%的MeOH在DCM中的溶液洗脱,得到作为白色泡沫的标题化合物(1.37g,66%)。LCMS(方法3):Rt2.60min,m/z370.2[MH+]。
c.{(1S,4R)-4-[2-(2-甲氧基-乙酰基氨基)-吡啶-4-基甲氧基]-1,2,3,4-四氢-萘-1-基}-氨基甲酸叔丁酯(中间体9c)
在氩气下,将中间体9b(1.37g,3.70mmol)溶解在DCM(25mL)中,并在冰浴中冷却。向该混合物中加入DIPEA(0.96mL,6.00mmol),然后加入甲氧基乙酰氯(0.36mL,4.00mmol)。将混合物在冷却下搅拌15min,然后用饱和碳酸氢钠溶液稀释,并在室温搅拌5min。分离各相,并将有机层干燥(Na2SO4)和蒸发。通过FCC进行纯化,用0-100%的乙酸乙酯在环己烷中的溶液洗脱,得到标题化合物(626mg,38%)。LCMS(方法3):Rt3.85min,m/z464.2[MNa+]。
d.N-[4-((1R,4S)-4-氨基-1,2,3,4-四氢-萘-1-基氧基甲基)-吡啶-2-基]-2-甲氧基-乙酰胺(中间体9d)
向中间体9c(0.62g,1.41mmol)在DCM(7mL)中的溶液中,加入三氟乙酸(1mL),并将混合物在室温搅拌3h。将溶液在SCX-2柱上纯化,用MeOH洗涤,然后用0.4-1M的NH3在MeOH中的溶液洗脱,得到不纯的标题化合物(0.42g)。通过FCC进行额外纯化,用0-14%[2M的NH3在MeOH中的溶液]在DCM中的溶液洗脱,得到作为无色胶状物的标题化合物(0.28g,58%)。LCMS(方法3):Rt0.44和2.06min,m/z364[MNa+]。
e.N-(4-{(1R,4S)-4-[3-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-脲基]-1,2,3,4-四氢-萘-1-基氧基甲基}-吡啶-2-基)-2-甲氧基-乙酰胺(实施例9)
向中间体9d(277mg,0.81mmol)在1,4-二噁烷(10mL)中的溶液中,加入(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-氨基甲酸-2,2,2-三氯-乙酯(SyntheticCommunications,39(22),3999-4009;2009;394mg,0.97mmol)和DIPEA(0.21mL,1.30mmol)。将混合物在氩气下在80℃加热16h,然后蒸发至干燥。通过FCC纯化残余物,用0-100%的乙酸乙酯在环己烷中的溶液洗脱,得到稍微不纯的标题化合物(378mg)。将其通过制备型HPLC(方法6)进一步纯化,得到作为白色固体的标题化合物(305mg,63%)。LCMS(方法5):Rt5.09min,m/z597.2[MH+]。1HNMR(400MHz,d6-DMSO):1.21(9H,s),1.76-1.87(2H,m),1.90-2.01(2H,m),2.31(3H,s),3.31(3H,s),4.00(2H,s),4.43-4.50(1H,m),4.57-4.76(3H,m),4.75-4.83(1H,m),6.27(1H,s),7.03(1H,d,J8.7Hz),7.06(1H,dd,J5.2,1.4Hz),7.15-7.32(7H,m),7.36-7.40(1H,m),7.93(1H,s),8.08(1H,s),8.22(1H,d,J5.2Hz),9.88(1H,brs)。
实施例10
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-{(1S,4R)-4-[3-(2-羟基-乙基硫烷基)-苯基]-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基-脲
a.2-{2-[5-氟-吡啶-2-基)-亚联氨基甲基(hydrazonomethyl)]-苯基硫烷基}-乙醇(中间体10a)
用与在实施例4步骤a中描述的操作类似的操作,从5-氟-2-肼基-吡啶(关于参考操作,参见WO2010022076)和2-(2-羟基-乙基硫烷基)-苯甲醛(关于参考操作,参见WO2009098612)开始,制备标题化合物。LCMS(方法1):Rt2.93min,m/z292[MH+]。
b.2-[2-(6-氟-[1,2,4]三唑并[4,3-a]吡啶-3-基)-苯基硫烷基]-乙醇(中间体10b)
用与在实施例4步骤b中描述的操作类似的操作,从中间体10a和(二乙酰氧基碘)苯开始,制备标题化合物。LCMS(方法1):Rt2.33min,m/z290[MH+]。
c.6-氟-3-[2-(2-三异丙基甲硅烷基氧基-乙基硫烷基)-苯基-[1,2,4]三唑并[4,3-a]吡啶(中间体10c)
将三异丙基甲硅烷基氯(3.30g,17.1mmol)加入到中间体10b(3.30g,11.4mmol)、咪唑(0.93g,13.7mmol)和DMAP(139mg,1.14mmol)在THF(35mL)中的溶液中,并将混合物在50℃加热过夜。将冷却的混合物用HCl(1M,15mL)洗涤。用2-甲基四氢呋喃(2×100mL)萃取水相。将合并的有机萃取物用盐水洗涤和干燥(MgSO4)。蒸发溶剂,并使用25-80%的环己烷在EtOAc中的溶液通过FCC纯化残余物,得到作为棕色油的标题化合物(3.45g,68%)。LCMS(方法2):Rt4.78min,m/z446[MH+]。
d.(1S,4R)-4-{3-[2(2-三异丙基甲硅烷基氧基-乙基硫烷基)-苯基]-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基}-1,2,3,4-四氢-萘-1-基胺(中间体10d)
用与在实施例1步骤g中描述的操作类似的操作,从中间体10c和中间体1d开始,制备标题化合物。LCMS(方法1):Rt3.02min,m/z589[MH+]。
e.1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[(1S,4R)-4-{3-[2-(2-三异丙基甲硅烷基氧基-乙基硫烷基)-苯基]-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲(中间体10e)
用与在实施例1步骤h中描述的操作类似的操作,从中间体10d和[5-叔丁基-2-对甲苯基-2H-吡唑-3-基]-氨基甲酸-2,2,2-三氯-乙酯(SyntheticCommunications,39(22),3999-4009;2009)开始,制备标题化合物。LCMS(方法4):Rt4.29min,m/z844[MH+]。
f.1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-{(1S,4R)-4-[3-(2-羟基-乙基硫烷基)-苯基]-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基-脲(实施例10)
在0℃,将三乙胺三氢氟酸盐(163mg,1.01mmol)逐份加入到中间体10e(428mg,0.51mmol)和THF(3.0mL)的溶液中。除去冰浴,并将混合物在室温搅拌过夜。将饱和NaHCO3水溶液(10mL)加入到混合物中,然后将其用乙酸乙酯(3×10mL)萃取。将合并的有机萃取物用盐水(15mL)洗涤和干燥(Na2SO4)。蒸发溶剂,并通过HPLC(用50-95%的MeCN在H2O(0.1%HCO2H)中的溶液洗脱)纯化残余物,得到作为无色粉末的标题化合物(8.0mg,2.2%)。LCMS(方法5):Rt4.72分钟,m/z=688[MH+]。1HNMR(400MHz,CDCl3):1.32(9H,s),1.81-2.07(3H,m),2.16-2.23(1H,m),2.36(3H,s),2.90(2H,t),3.59(2H,t),5.02(1H,m),5.11(1H,m),5.25(1H,m),6.25(1H,s),6.30(1Hbrs),7.12(1H,m),7.19-7.38(10H,m),7.44-7.57(3H,m),7.69-7.73(2H,m)。
实施例11
1-{5-叔丁基-2-[3-(2-二甲基氨基-乙氧基)-苯基]-2H-吡唑-3-基}-3-[(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲
a.5-叔丁基-2-(3-甲氧基-苯基)-2H-吡唑-3-基胺(中间体11a)
将3-甲氧基苯基肼盐酸盐(5.00g,28.6mmol)和4,4-二甲基-3-氧代戊烷腈(oxopentanenitrile)(3.94g,31.5mmol)在MeOH中加热至100℃保持18h。将反应物冷却,并在真空中蒸发。将残余物溶解于EtOAc(200mL)和水(200mL)中,并用EtOAc(3×)萃取水层。将合并的有机层用盐水洗涤,干燥(MgSO4)、过滤和在真空中蒸发。使用0-50%的EtOAc在环己烷中的溶液,通过FCC进行纯化,得到标题化合物(5.03g),作为与4,4-二甲基-3-氧代戊烷腈的混合物。将其不经进一步纯化用于下一反应。1HNMR(400MHz,d6-DMSO):1.21(9H,s),3.79(3H,s),5.20(2H,brs),5.37(1H,s),6.82-6.85(1H,dd,J8.3,2.2Hz),7.12-7.17(2H,m),7.32-7.36(1H,t,J8.1Hz)。
b.3-(5-氨基-3-叔丁基-吡唑-1-基)-苯酚(中间体11b)
将氯化铝(13.6g,102.6mmol)逐份加入到中间体11a(5.03g)在DCM(50.0mL)中的溶液中,并将反应物加热至45℃保持18h。加入额外的氯化铝(4.00g,30.0mmol),并将反应物加热至45℃保持另外18h。将混合物冷却,并缓慢地转移进冰冷水中,然后萃取进EtOAc(3×)中。将合并的有机层用盐水洗涤,干燥(MgSO4)、过滤和在真空中蒸发。使用0-50%的EtOAc在环己烷中的溶液,通过FCC进行纯化,得到标题化合物(2.40g,10.4mmol,36%)。LCMS(方法1):Rt2.03分钟,m/z232[MH+]。
c.5-叔丁基-2-[3-(2-二甲基氨基-乙氧基)-苯基]-2H-吡唑-3-基胺(中间体11c)
将DIAD(847μL,4.32mmol)缓慢地加入到中间体11b(500mg,2.16mmol)、2-二甲基氨基乙醇(326μL,3.25mmol)和三苯基膦(1.13g,4.32mmol)在THF(10mL)中的溶液中,并将反应物搅拌72h。将反应混合物在EtOAc(75mL)和H2O(75mL)之间分配,并用EtOAc(3×)萃取水层。将合并的有机层用盐水洗涤,干燥(MgSO4)、过滤和在真空中蒸发。使用0.5-6%[2M的NH3在MeOH中的溶液]在DCM中的溶液,通过FCC进行纯化,得到标题化合物(472mg,1.56mmol,72%)。LCMS(方法4):Rt0.32min,m/z303[MH+]。
d.{5-叔丁基-2-[3-(2-二甲基氨基-乙氧基)-苯基]-2H-吡唑-3-基}-氨基甲酸-2,2,2-三氯-乙酯(中间体11d)
将中间体11c(100mg,0.33mol)溶解在THF(3.0mL)中,并加入DIPEA(115μL,0.66mmol),随后加入氯甲酸-2,2,2-三氯乙酯(68μL,0.50mmol)。将反应物搅拌60min,然后在EtOAc(50mL)和H2O(50mL)之间分配,并用EtOAc(3×)萃取水层。将合并的有机层用盐水洗涤,干燥(MgSO4)、过滤和在真空中蒸发,得到被二酰化物污染的标题化合物(130mg)。将其不经进一步纯化用于下一步。LCMS(方法2):Rt2.95min,m/z475,479[M-H-]。
e.1-{5-叔丁基-2-[3-(2-二甲基氨基-乙氧基)-苯基]-2H-吡唑-3-基}-3-[(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲(实施例11)
将二异丙基乙胺(81μL,0.30mmol)加入到中间体1g(105mg,0.32mmol)和中间体11d(122mg)在1,4-二噁烷(3.0mL)中的溶液中。将反应物加热至100℃保持18h。冷却后,将混合物在EtOAc(50mL)和水(50mL)之间分配。将水层萃取进EtOAc(3×)中,并将合并的有机层用盐水洗涤、干燥(MgSO4)和在真空中浓缩。使用0-10%[2M的NM3在MeOH中的溶液]在DCM中的溶液,通过FCC进行纯化,得到粗产物。通过HPLC(C18X-select柱,10-98%的MeCN在H2O中的溶液,0.1%甲酸)进一步纯化,得到标题化合物(22mg,0.033mmol,11%)。LCMS(方法5):Rt3.40分钟,m/z651[MH+]。1HNMR(400MHz,CDCl3):1.31(9H,s),1.43-1.46(3H,d,J6.8Hz),1.46-1.49(3H,d,J6.8Hz),1.90-2.20(4H,m),2.43(6H,s),2.89-2.95(1H,dd,J13.3,5.2Hz),2.95-3.01(1H,dd,J13.3,5.2Hz),3.20-3.30(1H,sp,J6.8Hz),4.23-4.28(2H,t,J5.2Hz),5.04-5.11(1H,td,J8.8,5.6Hz),5.14-5.18(1H,t,J4.2Hz),6.42(1H,s),6.42-6.48(1H,brs),6.81-6.85(1H,dd,J8.3,1.9Hz),6.98-7.00(1H,t,J4.3Hz),7.00-7.04(1H,dd,J9.9,1.9Hz),7.12-7.16(1H,m),7.22-7.34(5H,m),7.43-7.44(1H,d,J1.7Hz),7.61-7.65(1H,d,J9.7Hz)。
从合适的起始原料开始,并在适当时使用与指出的那些类似的操作,制备下述实施例。
实施例28
N-(5-叔丁基-3-{3-[(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲基}-2-甲氧基-苯基)-甲磺酰胺
用与在实施例6步骤b和实施例1步骤h中描述的那些类似的操作,使用5-叔丁基-3-甲磺酰氨基-2-甲氧基苯胺(关于参考操作,参见WO2005023761)和中间体1g,制备标题化合物。LCMS(方法5)Rt4.30min,m/z621.2[MH+];1HNMR(400MHz,CDCl3):1.28(9H,s),1.42-1.45(3H,d,J6.9Hz),1.45-1.48(3H,d,J6.9Hz),2.00-2.20(3H,m),2.23-2.30(1H,m),3.02(3H,s),3.20-3.28(1H,sp,J6.9Hz),3.74(3H,s),5.12-5.20(1H,m),5.18-5.21(1H,t,J4.4Hz),5.62-5.66(1H,d,J8.8Hz),6.88(1H,s),6.99-7.03(1H,dd,J9.8,2.0Hz),7.06(1H,s),7.23-7.35(4H,m),7.43-7.45(1H,d,J1.8Hz),7.47-7.50(1H,d,J7.7Hz),7.60-7.64(1H,d,J9.9Hz),7.75-7.77(1H,d,J2.3Hz)。
实施例29
1-(3-氟-5-吗啉-4-基-苯基)-3-[(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲
用与在实施例6步骤b和实施例1步骤h中描述的那些类似的操作,使用3-氟-5-(吗啉-4-基)苯胺(烯胺)和中间体1g,制备标题化合物。LCMS(方法5)Rt3.98min,m/z545.1[MH+];1HNMR(400MHz,CDCl3):1.41-1.44(3H,d,J6.8Hz),1.44-1.48(3H,d,J6.8Hz),2.00-2.20(3H,m),2.24-2.32(1H,m),3.10-3.14(4H,t,J4.7Hz),3.20-3.32(1H,brs),3.76-3.82(4H,t,J4.8Hz),5.12-5.24(2H,m),6.20-6.28(2H,d,J11.7Hz),6.58-6.62(1H,d,J10.0Hz),6.90-6.96(1H,m),7.01-7.03(1H,brs),7.22-7.34(3H,m),7.38-7.46(1H,brs),7.50-7.56(2H,m)。
实施例30
1-(3-氟-5-吗啉-4-基-苯基)-3-[(1S,4S)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲
用与在实施例6步骤b和实施例1步骤h中描述的操作类似的操作,使用3-氟-5-(吗啉-4-基)苯胺(烯胺)和中间体2c,制备标题化合物。LCMS(方法5):Rt3.92min,m/z545[MH+];1HNMR(400MHz,d6-DMSO):1.38(3H,d),1.40(3H,d),1.80(1H,m),2.04(1H,m),2.20(2H,m),3.07(4H,dd),3.58(1H,七重峰),3.71(4H,dd),4.97(1H,m),5.62(1H,m),6.35(1H,ddd),6.64(1H,d),6.72(1H,m),6.81(1H,ddd),7.24(1H,dd),7.29-7.40(3H,m),7.43(1H,d),7.69(1H,d),8.23(1H,m),8.40(1H,s)。
实施例31
1-{5-叔丁基-2-(4-氟-3-吗啉-4-基甲基-苯基)-2H-吡唑-3-基}-3-[(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲
a.4-(5-溴-2-氟-苄基)-吗啉(中间体31a)
将2-溴-5-氟苯甲醛(2.50g,12.30mmol)、吗啉(1.62g,18.50mmol)和乙酸(0.42mL),7.40mmol)在1,2-二氯乙烷(50mL)中的溶液在氮气下在室温搅拌0.5h。然后加入三乙酰氧基硼氢化钠(3.92g,12.30mmol),并将混合物搅拌6h。加入饱和碳酸氢钠溶液(50mL),并将混合物剧烈搅拌0.5h。分离有机相,并用DCM(2×30mL)进一步萃取水相。将合并的有机萃取物用水(100mL)洗涤和干燥(Na2SO4)。蒸发溶剂,并通过FCC纯化残余物,用0-50%的EtOAc在戊烷中的溶液洗脱,得到作为无色油的标题化合物(1.93g,57%)。LCMS(方法1):Rt1.42min,m/z274/276[MH+]。
b.1-[4-氟-3-(吗啉-4-基甲基)苯基]肼-1,2-二甲酸二叔丁酯(中间体31b)
在-78℃在氮气下,将正丁基锂(1.6M的在己烷类中的溶液,5.7mL,9.15mmol)逐滴加入到中间体31a(1.93g,7.04mmol)在无水THF(15mL)中的搅拌溶液中。将混合物在-78℃搅拌10min,然后一次性加入偶氮二甲酸二叔丁酯(1.78g,7.74mmol)。将混合物在-78℃搅拌20min,然后历时20min将其温热至室温。将混合物在饱和氯化铵(15mL)溶液和乙酸乙酯(3×20mL)之间分配。将合并的有机萃取物用盐水(20mL)洗涤和干燥(Na2SO4)。蒸发溶剂,并通过FCC纯化残余物,用0-100%的EtOAc在戊烷中的溶液洗脱,得到作为淡黄色泡沫的标题化合物(0.71g,24%)。LCMS(方法1):Rt2.35min,m/z426[MH+]。
c.5-叔丁基-2-(4-氟-3-吗啉-4-基甲基-苯基)-2H-吡唑-3-基胺(中间体31c)
将中间体31b(0.71g,1.67mmol)、新戊酰基乙腈(0.21g,1.67mmol)和浓盐酸(0.84mL)在乙醇(6mL)中的混合物在回流下加热3h。用饱和NaHCO3水溶液将冷却的混合物调至约pH7,并将混合物在水(10mL)和EtOAc(3×15mL)之间分配。将合并的有机萃取物用盐水(15mL)洗涤和干燥(Na2SO4)。蒸发溶剂,并将残余物研磨(乙醚),得到作为淡黄色固体的标题化合物(239mg,43%)。LCMS(方法1):Rt1.68min,m/z333[MH+]。
d.[5-叔丁基-2-(4-氟-3-吗啉-4-基甲基-苯基)-2H-吡唑-3-基]-氨基甲酸-2,2,2-三氯-乙酯(中间体31d)
将氯甲酸-2,2,2-三氯乙酯(0.097mL,0.72mmol)加入到中间体31c(239mg,0.72mmol)和DIPEA(0.38mL,2.16mmol)在THF(5mL)中的溶液中,并将混合物搅拌1h。然后将混合物在水(10mL)和EtOAc(3×15mL)之间分配,并将合并的有机萃取物干燥(Na2SO4)。蒸发溶剂,得到作为淡黄色胶状物的标题化合物(218mg,60%)。LCMS(方法1):Rt2.67min,m/z507/509[MH+]。
e.1-{5-叔丁基-2-(4-氟-3-吗啉-4-基甲基-苯基)-2H-吡唑-3-基}-3-[(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲(实施例31)
用与在实施例1步骤h中描述的操作类似的操作,使用中间体31d和中间体1g,制备标题化合物。LCMS(方法5):Rt3.31min,m/z681[MH+];1HNMR(300MHz,CDCl3):1.33(9H,s),1.48(6H,dd,J6.8,12.4Hz),1.90-2.03(1H,m),2.05-2.16(2H,m),2.24-2.31(1H,m),2.50(3H,brs),3.21-3.31(1H,m),3.59(2H,brs),3.68(5H,brs),5.06-5.13(1H,m),5.18-5.21(1H,m),5.49(1H,brs),6.32(1H,brs),6.53(1H,brs),7.02-7.07(1H,m),7.08-7.16(1H,m),7.29(4H,brs),7.45(2H,brs),7.57-7.64(2H,m)。
实施例32
1-[5-叔丁基-2-(3-氯-4-羟基-苯基)-2H-吡唑-3-基]-3-((1S,4R)-4-{3-[2-(2-羟基-乙基硫烷基)-苯基]-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基}-1,2,3,4-四氢-萘-1-基)-脲
a.[5-叔丁基-2-(3-氯-4-三异丙基甲硅烷基氧基-苯基)-2H-吡唑-3-基]-氨基甲酸-2,2,2-三氯-乙酯(中间体32a)
将氯甲酸三氯乙酯(2.76g,13.0mmol)逐滴加入到5-叔丁基-2-(3-氯-4-三异丙基甲硅烷基氧基-苯基)-2H-吡唑-3-基胺(关于参考操作,参见WO2009098612;4.21g,10.0mmol)和二异丙基乙胺(3.87g,30.0mmol)在THF(100mL)中的溶液中。将该混合物在室温搅拌20h。将得到的混合物用乙酸乙酯稀释,然后用水洗涤,干燥(MgSO4)和在真空中蒸发,然后使用0-30%的乙酸乙酯在环己烷中的溶液,通过FCC进行纯化,得到标题化合物(3.51g,5.89mmol,58%)。LCMS(方法1):Rt5.86min,m/z596/597[MH+]。
b.1-[5-叔丁基-2-(3-氯-4-羟基-苯基)-2H-吡唑-3-基]-3-((1S,4R)-4-{3-[2-(2-羟基-乙基硫烷基)-苯基]-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基}-1,2,3,4-四氢-萘-1-基)-脲(实施例32)
将中间体10d(25mg,0.043mmol)、中间体32a(51mg,0.085mmol)和二异丙基乙胺(22mg,0.171mmol)溶解在DMF(2.0mL)中,并在60℃搅拌30min。冷却后,使用SCX-2柱纯化混合物,用MeOH洗涤,并用2M的NH3在MeOH中的溶液洗脱,得到残余物。将其溶解在THF(1.0mL)中,并加入三乙胺-三氢氟酸盐(4滴)。将该混合物在室温放置20h,然后用饱和碳酸氢钠溶液(10mL)稀释,并用乙酸乙酯(3×)萃取。在真空中蒸发合并的有机萃取物。通过HPLC(C18X-select柱,35-55%的MeCN在H2O中的溶液,0.1%甲酸)进行纯化,得到标题化合物(5.0mg,16%)。LCMS(方法5):Rt4.43min,m/z724.2[MH+]。1HNMR(400MHz,d4-MeOD):1.32(9H,s),1.86-2.11(4H,m),2.21-2.30(1H,m),2.97-3.03(2H,dt,J6.6,2.6Hz),3.61(2H,t,J6.63Hz),4.75(1H,brs),5.35(1H,t,J3.88Hz),6.31(1H,s),6.99(1H,d,J8.26Hz),7.18-7.25(3H,m),7.26-7.34(2H,m),7.37(1H,dd,J10.26,2.13Hz),7.41(1H,d,J2.63Hz),7.46(1H,dt,J7.63,1.0Hz),7.53-7.58(2H,m),7.63(1H,dt,J7.5,1.8Hz),7.72(1H,d,J8.26Hz),7.78(1H,dd,J10.1,0.88Hz),8.55(1H,s)。
实施例33
1-[5-叔丁基-2-(3-氯-4-羟基-苯基)-2H-吡唑-3-基]-3-((1S,4S)-4-{3-[2-(2-羟基-乙基硫烷基)-苯基]-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基}-1,2,3,4-四氢-萘-1-基)-脲
将(1S,4S)-4-{3-[2-(2-三异丙基甲硅烷基氧基-乙基硫烷基)-苯基]-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基}-1,2,3,4-四氢-萘-1-基胺(用与在实施例10步骤d中描述的那些类似的操作制备:25mg,0.043mmol)、中间体32a(51mg,0.085mmol)和二异丙基乙胺(22mg,0.171mmol)溶解在DMF(2.0mL)中,并在60℃搅拌30min。冷却后,使用SCX-2柱纯化混合物,用MeOH洗涤,并用2M的NH3在MeOH中的溶液洗脱,得到残余物。将其溶解在THF(1.0mL)中,并加入三乙胺-三氢氟酸盐(4滴)。将该混合物在室温放置20h,并将混合物用饱和碳酸氢钠溶液(10mL)稀释,并用乙酸乙酯(3×)萃取。将合并的有机萃取物在真空中蒸发,然后通过HPLC(C18X-select柱,35-55%的MeCN在H2O中的溶液,0.1%甲酸)进一步纯化,得到标题化合物(2.0mg,6.5%)。LCMS(方法5):Rt4.43min,m/z724.2[MH+]。1HNMR(400MHz,d4-MeOD):1.31(9H,s),1.71-1.80(1H,m),2.10-2.20(4H,m),2.99(2H,dt,J6.7,1.7Hz),3.60(2H,t,J6.5Hz),4.51(1H,brs),4.97(1H,t,J5.5Hz),5.41(1H,t,J4.9Hz),6.29(1H,s),6.90(1H,d,J8.2Hz),7.16-7.25(3H,m),7.27-7.31(2H,m),7.36-7.41(2H,m),7.43-7.48(1H,m),7.53(1H,dd,J7.7,1.5Hz),7.63(1H,dt,J7.5,1.2Hz),7.72(1H,dd,J8.1,0.7Hz),7.77(1H,d,J10.0Hz),8.55(1H,s)。
实施例34
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-{(1S,4R)-4-[3-(2-吡咯烷-1-基-吡啶-4-基)-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基]-1,2,3,4-四氢-萘-1-基}-脲,甲酸盐
a.6-氟-[1,2,4]三唑并[4,3-a]吡啶(中间体34a)
将5-氟-2-肼基-吡啶(关于参考操作,参见WO2010022076;1.00g,7.87mmol)溶解在乙酸二乙氧基甲酯(10mL)中并搅拌90min。将得到的固体过滤,用环己烷洗涤,并在真空中干燥,得到标题化合物(904mg,84%)。1HNMR(400MHz,CDCl3):7.21-7.29(1H,ddd,J9.8,7.7,2.3Hz),7.80-7.87(1H,dd,J9.9,4.8Hz),8.07-8.09(1H,m),8.84(1H,s)。
b.3-溴-6-氟-[1,2,4]三唑并[4,3-a]吡啶(中间体34b)
将中间体34a(908mg,6.60mmol)溶解在DCM(50mL)中,并加入N-溴琥珀酰亚胺(1.29g,7.26mmol)。将反应物加热至45℃保持4h,然后冷却,并在DCM(150mL)和饱和NaHCO3水溶液(150mL)之间分配,并萃取进DCM(3×)中。将合并的有机层用盐水洗涤,干燥(MgSO4)和在真空中蒸发。使用0-5%[2M的NH3在MeOH中的溶液]在DCM中的溶液,通过FCC进行纯化,得到标题化合物(900mg,63%)。LCMS(方法1):Rt1.94min,m/z216/218[MH+]。
c.6-氟-3-(2-吡咯烷-1-基-吡啶-4-基)-[1,2,4]三唑并[4,3-a]吡啶(中间体34c)
将脱气的(用氩气鼓泡10min)二噁烷/水(2:1,9.0mL)加入到中间体34b(200mg,0.93mmol)、5-(吡咯烷子基)(pyrrolidino)吡啶-3-硼酸频哪醇酯(304mg,1.11mmol)、碳酸钠(296mg,2.79mmol)和四三苯基膦钯(54.0mg,0.046mmol)中。将反应物加热至85℃保持5h,然后冷却。将混合物在EtOAc(50mL)和水(50mL)之间分配,并萃取进EtOAc(3×)中。将合并的有机层用盐水洗涤,干燥(MgSO4)和在真空中蒸发。使用0-10%的MeOH在DCM中的溶液,通过FCC进行纯化,得到标题化合物(200mg,0.71mmol,76%)。LCMS(方法1):Rt0.34min,1.72min,m/z284[MH+]。
d.(1S,4R)-4-[3-(2-吡咯烷-1-基-吡啶-4-基)-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基]-1,2,3,4-四氢-萘-1-基胺(中间体34d)
将中间体1d(115mg,0.71mmol)加入到氢化钠(60%的在矿物油中的溶液,85.0mg,2.12mmol)在DMF(2mL)中的混悬液中。将反应物搅拌20min,然后加入中间体34c(200mg,0.71mmol)在DMF(2mL)中的溶液,并将反应物加热至60℃保持2h。冷却后,通过逐滴加入MeOH,淬灭反应。将溶液用MeOH稀释,并加载到SCX-2柱上,将该柱依次用MeOH和2M的NH3在MeOH中的溶液洗涤。在真空中蒸发碱性级分,然后使用0-10%[2M的NH3在MeOH中的溶液]在DCM中的溶液,通过FCC进行纯化,得到被几种杂质污染的标题化合物(70mg)。将反应物不经进一步纯化进入下一步。
e.1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-{(1S,4R)-4-[3-(2-吡咯烷-1-基-吡啶-4-基)-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基]-1,2,3,4-四氢-萘-1-基}-脲甲酸盐(实施例34)
向中间体34d(70mg)溶解在1,4-二噁烷(2mL)中的溶液中,加入(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-氨基甲酸-2,2,2-三氯-乙酯(SyntheticCommunications,39(22),3999-4009;2009;62.0mg,0.15mmol)和DIPEA(56.0μL,0.30mmol)。将得到的反应物加热至60℃保持18h。冷却后,将混合物在EtOAc(50mL)和水(50mL)之间分配,并萃取进EtOAc(3×)中。将合并的有机层用盐水洗涤,干燥(MgSO4)和在真空中蒸发。使用0-10%[2M的NH3在MeOH中的溶液]在DCM中的溶液,通过FCC纯化残余物,然后通过HPLC(C18X-select柱,10-60%的MeCN在H2O中的溶液,0.1%甲酸)进一步纯化,得到作为部分地呈甲酸盐形式的标题化合物(15.0mg,0.022mmol,3%)。LCMS(方法5)Rt4.18min,m/z682[MH+]。1HNMR(400MHz,d4-MeOD):1.29(9H,s),1.90-2.10(7H,m),2.20-2.30(1H,m),2.38(3H,s),3.47-3.55(4H,m),4.84-4.90(1H,dd,J6.0,8.8),5.36-5.40(1H,t,J4.1),6.32(1H,s),6.64-6.68(1H,d,J9.0),7.19-7.34(11H,m),7.67-7.71(1H,d,J10.0),7.84-7.88(1H,dd,J9.0,2.3),7.90-7.92(1H,d,J1.7),8.42-8.44(1H,d,J2.3),8.50(0.7H,brs,甲酸盐)。
生物学测定
P38α酶抑制测定
使用基于(PerkinElmer)的激酶活性测定,确定化合物的抑制活性。激酶反应物由25mMHEPES(pH7.5)、10mMMgCl2、100μMNa3VO4、2mMDTT、0.05mg/ml吐温20、100pMp38α(Invitrogen,PV3304)、1%DMSO和0.3μg/mlATF-2融合蛋白(NewEnglandBiolabs,9224)组成。将化合物在这些条件下在25℃温育2小时,然后通过加入250μMATP,开始激酶活性。反应体积为20uL。在25℃保持1hr以后,通过加入10μL含有62.5mMEDTA、0.05%TritonX-100、10%BSA和0.83ng/μL抗-磷酸-ATF2抗体(Abcam,ab28812)的25mMHEPES(pH7.5),停止反应。通过测量加入AlphascreenDonor珠子(beads)(PerkinElmer6765300)和蛋白AAlphascreenAcceptor珠子(PerkinElmer6760137)(二者的终浓度为20μg/ml)以后的发光,进行检测。从浓度-响应曲线确定IC50值。
结果显示在下表中:
实施例 | p38α抑制 |
1 | ++++ |
2 | ++++ |
3 | ++++51 --> |
4 | ++++ |
5 | ++++ |
6 | ++++ |
7 | ++++ |
8 | ++++ |
9 | ++++ |
10 | ++++ |
11 | ++++ |
12 | ++++ |
13 | +++ |
14 | ++++ |
15 | ++++ |
16 | ++++ |
17 | ++++ |
18 | ++++ |
19 | ++++ |
20 | ++++ |
21 | ++++ |
22 | ++++ |
23 | ++++ |
24 | ++++ |
25 | ++++ |
26 | ++++ |
27 | ++++ |
28 | ++++ |
29 | ++++ |
30 | ++++ |
31 | ++++ |
在上表中,如下指示p38α结合能力(IC50值):7000-500nM‘+’;500-100nM‘++’;100-10nM‘+++’;<10nM‘++++’。
Claims (8)
1.化合物,所述化合物选自:
1-(5-叔丁基-2-苯基-2H-吡唑-3-基)-3-[4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-环丙基-3-[4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[3-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基硫烷基)-茚满-1-基]-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[4-{3-[3-(2-吗啉-4-基-乙氧基)-苯基]-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基}-1,2,3,4-四氢-萘-1-基)-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-7-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-{5-叔丁基-2-[3-(2-吗啉-4-基-乙氧基)-苯基]-2H-吡唑-3-基}-3-[4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-(5-叔丁基-异噁唑-3-基)-3-[3-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-茚满-1-基]-脲;
1-{5-叔丁基-2-[3-(2-二甲基氨基-乙氧基)-苯基]-2H-吡唑-3-基}-3-[4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-[5-叔丁基-2-(4-羟基-苯基)-2H-吡唑-3-基]-3-[4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[4-(3-环戊基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-[5-叔丁基-2-(3-吗啉-4-基甲基-苯基)-2H-吡唑-3-基]-3-[4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[4-(3-环丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基}-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[4-(3-吡啶-2-基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基}-脲;
1-[5-叔丁基-2-(3-氯-4-羟基-苯基)-2H-吡唑-3-基]-3-[4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[4-(3-环己基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-[5-叔丁基-2-(4-氯-3-羟基-苯基)-2H-吡唑-3-基]-3-[4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-(3-氟-5-吗啉-4-基-苯基)-3-[4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-{5-叔丁基-2-(4-氟-3-吗啉-4-基甲基-苯基)-2H-吡唑-3-基}-3-[4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-[5-叔丁基-2-(3-氯-4-羟基-苯基)-2H-吡唑-3-基]-3-(4-{3-[2-(2-羟基-乙基硫烷基)-苯基]-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基}-1,2,3,4-四氢-萘-1-基)-脲;
1-[5-叔丁基-2-(3-氯-4-羟基-苯基)-2H-吡唑-3-基]-3-(4-{3-[2-(2-羟基-乙基硫烷基)-苯基]-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基}-1,2,3,4-四氢-萘-1-基)-脲;和
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-{4-[3-(2-吡咯烷-1-基-吡啶-4-基)-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基]-1,2,3,4-四氢-萘-1-基}-脲,
或其药学上可接受的盐。
2.化合物,所述化合物选自:
1-(5-叔丁基-2-苯基-2H-吡唑-3-基)-3-[(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-环丙基-3-[(1S,4S)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
(±)-反式-1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[3-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基硫烷基)-茚满-1-基]-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[(1S,4R)-4-{3-[3-(2-吗啉-4-基-乙氧基)-苯基]-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基}-1,2,3,4-四氢-萘-1-基)-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-7-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-{5-叔丁基-2-[3-(2-吗啉-4-基-乙氧基)-苯基]-2H-吡唑-3-基}-3-[(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-{(1S,4R)-4-(3-(2-羟基-苯基)-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基}-脲;
1-(5-叔丁基-异噁唑-3-基)-3-[(1S,3S)-3-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-茚满-1-基]-脲;
N-(4-{(1R,4S)-4-[3-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-脲基]-1,2,3,4-四氢-萘-1-基氧基甲基}-吡啶-2-基)-2-甲氧基-乙酰胺;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-{(1S,4R)-4-[3-(2-羟基-乙基硫烷基)-苯基]-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基-脲;
1-{5-叔丁基-2-[3-(2-二甲基氨基-乙氧基)-苯基]-2H-吡唑-3-基}-3-[(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-[5-叔丁基-2-(3-氯-4-羟基-苯基)-2H-吡唑-3-基]-3-[(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-环丙基-3-[(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-(5-叔丁基-2-(4-氯-3-羟基苯基)-2H-吡唑-3-基)-3-[(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢萘-1-基]-脲;
1-[5-叔丁基-2-(4-羟基-苯基)-2H-吡唑-3-基]-3-[(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[(1S,4R)-4-(3-叔丁基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-(5-叔丁基-异噁唑-3-基)-3-[(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[(1S,4R)-4-(3-环戊基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-[5-叔丁基-2-(3-吗啉-4-基甲基-苯基)-2H-吡唑-3-基]-3-[(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基-3-{(1S,4R)-4-(3-(2,6-二氯-苯基)-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基}-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基-3-基)-3-[(1S,4R)-4-(3-环丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基}-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基-3-基)-3-[(1S,4R)-4-(3-吡啶-2-基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基}-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基-3-{(1S,4R)-4-(3-(2-氯-苯基)-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基}-脲;
1-{(1S,4R)-4-[3-(2-苄氧基-苯基)-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基}-3-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-脲;
1-[5-叔丁基-2-(3-氯-4-羟基-苯基)-2H-吡唑-3-基]-3-[(1S,4S)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-[(1S,4R)-4-(3-环己基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-[5-叔丁基-2-(4-氯-3-羟基-苯基)-2H-吡唑-3-基]-3-[(1S,4S)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
N-(5-叔丁基-3-{3-[(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲基}-2-甲氧基-苯基)-甲磺酰胺;
1-(3-氟-5-吗啉-4-基-苯基)-3-[(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-(3-氟-5-吗啉-4-基-苯基)-3-[(1S,4S)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-{5-叔丁基-2-(4-氟-3-吗啉-4-基甲基-苯基)-2H-吡唑-3-基}-3-[(1S,4R)-4-(3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基)-1,2,3,4-四氢-萘-1-基]-脲;
1-[5-叔丁基-2-(3-氯-4-羟基-苯基)-2H-吡唑-3-基]-3-((1S,4R)-4-{3-[2-(2-羟基-乙基硫烷基)-苯基]-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基}-1,2,3,4-四氢-萘-1-基)-脲;
1-[5-叔丁基-2-(3-氯-4-羟基-苯基)-2H-吡唑-3-基]-3-((1S,4S)-4-{3-[2-(2-羟基-乙基硫烷基)-苯基]-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基}-1,2,3,4-四氢-萘-1-基)-脲;和
1-(5-叔丁基-2-对甲苯基-2H-吡唑-3-基)-3-{(1S,4R)-4-[3-(2-吡咯烷-1-基-吡啶-4-基)-[1,2,4]三唑并[4,3-a]吡啶-6-基氧基]-1,2,3,4-四氢-萘-1-基}-脲;
或其药学上可接受的盐。
3.化合物,所述化合物是式(Ia)的化合物:
其中基团R1选自:
-3-[3-(2-吗啉-4-基-乙氧基)-苯基]-[1,2,4]三唑并[4,3-a]吡啶-6-基;
-3-异丙基-[1,2,4]三唑并[4,3-a]吡啶-7-基;
-3-环戊基-[1,2,4]三唑并[4,3-a]吡啶-6-基;
-3-环丙基-[1,2,4]三唑并[4,3-a]吡啶-6-基;
-3-吡啶-2-基-[1,2,4]三唑并[4,3-a]吡啶-6-基;
-3-环己基-[1,2,4]三唑并[4,3-a]吡啶-6-基;
-3-(2-吡咯烷-1-基-吡啶-4-基)-[1,2,4]三唑并[4,3-a]吡啶-6-基;
或其药学上可接受的盐。
4.化合物,所述化合物是式(Ib)的化合物
其中基团R2选自:
-5-叔丁基-2-苯基-2H-吡唑-3-基;
-环丙基;
-5-叔丁基-2-[3-(2-吗啉-4-基-乙氧基)-苯基]-2H-吡唑-3-基;
-5-叔丁基-2-[3-(2-二甲基氨基-乙氧基)-苯基]-2H-吡唑-3-基;
-5-叔丁基-2-(3-氯-4-羟基-苯基)-2H-吡唑-3-基;
-5-叔丁基-2-(4-氯-3-羟基苯基)-2H-吡唑-3-基;
-5-叔丁基-2-(4-羟基-苯基)-2H-吡唑-3-基;
-5-叔丁基-2-(3-吗啉-4-基甲基-苯基)-2H-吡唑-3-基;
-3-氟-5-吗啉-4-基-苯基;
-5-叔丁基-2-(4-氟-3-吗啉-4-基甲基-苯基)-2H-吡唑-3-基;
或其药学上可接受的盐。
5.药物组合物,其包含在前述权利要求中的任一项中要求保护的化合物以及一种或多种药学上可接受的载体。
6.权利要求5中要求保护的组合物,所述组合物适合用于吸入进行肺给药。
7.权利要求1-4中的任一项中要求保护的化合物在制备药物中的用途,所述药物用于治疗受益于p38MAP激酶活性抑制的疾病或病症。
8.根据权利要求7所述的用途,其中所述疾病或病症是慢性嗜酸性粒细胞性肺炎,哮喘,慢性阻塞性肺疾病,成人呼吸窘迫综合征,因其它药物治疗所发生的气道高反应性的恶化,或与肺动脉高压有关的气道疾病。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2011/072375 WO2013083206A1 (en) | 2011-12-09 | 2011-12-09 | Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphtalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103987708A CN103987708A (zh) | 2014-08-13 |
CN103987708B true CN103987708B (zh) | 2016-06-22 |
Family
ID=45463549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180075375.9A Expired - Fee Related CN103987708B (zh) | 2011-12-09 | 2011-12-09 | 4-羟基-1,2,3,4-四氢萘-1-基脲的衍生物及其在呼吸道疾病治疗中的用途 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9458154B2 (zh) |
EP (1) | EP2788345B1 (zh) |
KR (1) | KR20140103925A (zh) |
CN (1) | CN103987708B (zh) |
BR (1) | BR112014013178A2 (zh) |
CA (1) | CA2858420A1 (zh) |
HK (1) | HK1199452A1 (zh) |
RU (1) | RU2586333C1 (zh) |
WO (1) | WO2013083206A1 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140105459A (ko) * | 2011-12-09 | 2014-09-01 | 키에시 파르마슈티시 엣스. 피. 에이. | 키나아제 억제제 |
WO2013083604A1 (en) | 2011-12-09 | 2013-06-13 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
US9181242B2 (en) | 2013-06-06 | 2015-11-10 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
GB201321742D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
AR107163A1 (es) | 2015-12-23 | 2018-03-28 | Chiesi Farm Spa | Inhibidores de quinasa |
US10364245B2 (en) | 2017-06-07 | 2019-07-30 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
NZ762856A (en) | 2017-10-05 | 2020-07-31 | Fulcrum Therapeutics Inc | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
CN108424372B (zh) * | 2018-05-11 | 2021-08-10 | 浙江华贝药业有限责任公司 | 2,2,2-三氟-n-[(s)-4-羰基四氢萘-1-基]-乙酰胺的纯化工艺 |
CN108707086B (zh) * | 2018-05-15 | 2021-08-10 | 浙江华贝药业有限责任公司 | 一种(1s,4s)-n-(4-羟基四氢萘-1-基)叔丁氧基碳酰胺的纯化工艺 |
CN108558695A (zh) * | 2018-05-15 | 2018-09-21 | 浙江华贝药业有限责任公司 | 2,2,2-三氟-n-[(1s,4s)-4-羟基四氢萘-1-基]-乙酰胺制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002092576A1 (en) * | 2001-05-16 | 2002-11-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Diarylurea derivatives useful as anti-inflammatory agents |
WO2007091152A1 (en) * | 2006-02-09 | 2007-08-16 | Pfizer Limited | Triazolopyridine compounds |
CN103140489A (zh) * | 2010-06-10 | 2013-06-05 | 奇斯药制品公司 | 脲衍生物和它们在治疗尤其是呼吸道疾病的治疗用途 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
EP0813534A4 (en) | 1995-03-10 | 1998-06-10 | Sanofi Winthrop Inc | 6-ARYL PYRAZOLO 3,4-D] PYRIMIDIN-4-ONES, COMPOSITIONS AND METHODS OF USE THEREOF |
WO1997002289A1 (en) | 1995-07-06 | 1997-01-23 | Zeneca Limited | Peptide inhibitors of fibronectine |
US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
UA73492C2 (en) * | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
DE60214428T2 (de) | 2001-12-20 | 2007-09-20 | Bayer Healthcare Ag | 1, 4-dihydro-1, 4-diphenylpyridin-derivate |
JP2003192587A (ja) * | 2001-12-26 | 2003-07-09 | Bayer Ag | 尿素誘導体 |
MXPA05008568A (es) | 2003-02-14 | 2005-11-04 | Pfizer Prod Inc | Nuevos compuestos anti-inflamatorios triazolo-piridinas. |
CN102060806A (zh) | 2003-09-11 | 2011-05-18 | iTherX药品公司 | 细胞因子抑制剂 |
SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
MX2007001759A (es) | 2004-08-12 | 2007-04-20 | Pfizer | Derivados de triazolopiridinilsulfanilo como inhbidores de proteina quinasa activada por mitogenos. |
US20090215817A1 (en) | 2004-08-18 | 2009-08-27 | Pfizer Inc | Novel Triazolopyridine Compounds for the Treatment of Inflammation |
GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
CA2634646C (en) | 2005-12-21 | 2012-04-10 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
CL2007002261A1 (es) | 2006-08-04 | 2008-05-02 | Takeda Pharmaceutical | Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer. |
WO2008043019A1 (en) | 2006-10-04 | 2008-04-10 | Pharmacopeia, Inc | 8-substituted 2-(benzimidazolyl) purine derivatives for immunosuppression |
US8222273B2 (en) | 2008-02-04 | 2012-07-17 | Pfizer Limited | Polymorphic form of a [1,2,4]triazole[4,3-A] pyridine derivative inflammatory diseases |
TWI496779B (zh) | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | 作為pim激酶抑制劑之三唑吡啶化合物 |
GB0818033D0 (en) * | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
CN102395586A (zh) * | 2009-02-17 | 2012-03-28 | 奇斯药制品公司 | 作为p38map激酶抑制剂的三唑并吡啶衍生物 |
KR20140105459A (ko) * | 2011-12-09 | 2014-09-01 | 키에시 파르마슈티시 엣스. 피. 에이. | 키나아제 억제제 |
WO2013083604A1 (en) * | 2011-12-09 | 2013-06-13 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
-
2011
- 2011-12-09 KR KR1020147014012A patent/KR20140103925A/ko not_active Application Discontinuation
- 2011-12-09 CN CN201180075375.9A patent/CN103987708B/zh not_active Expired - Fee Related
- 2011-12-09 BR BR112014013178A patent/BR112014013178A2/pt not_active Application Discontinuation
- 2011-12-09 EP EP11805445.1A patent/EP2788345B1/en active Active
- 2011-12-09 WO PCT/EP2011/072375 patent/WO2013083206A1/en active Application Filing
- 2011-12-09 US US14/363,556 patent/US9458154B2/en active Active
- 2011-12-09 CA CA2858420A patent/CA2858420A1/en not_active Abandoned
- 2011-12-09 RU RU2014123029/04A patent/RU2586333C1/ru not_active IP Right Cessation
-
2014
- 2014-12-31 HK HK14113104.0A patent/HK1199452A1/zh not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002092576A1 (en) * | 2001-05-16 | 2002-11-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Diarylurea derivatives useful as anti-inflammatory agents |
WO2007091152A1 (en) * | 2006-02-09 | 2007-08-16 | Pfizer Limited | Triazolopyridine compounds |
CN103140489A (zh) * | 2010-06-10 | 2013-06-05 | 奇斯药制品公司 | 脲衍生物和它们在治疗尤其是呼吸道疾病的治疗用途 |
Also Published As
Publication number | Publication date |
---|---|
RU2586333C1 (ru) | 2016-06-10 |
CN103987708A (zh) | 2014-08-13 |
KR20140103925A (ko) | 2014-08-27 |
US20150057273A1 (en) | 2015-02-26 |
US9458154B2 (en) | 2016-10-04 |
EP2788345B1 (en) | 2020-06-10 |
HK1199452A1 (zh) | 2015-07-03 |
EP2788345A1 (en) | 2014-10-15 |
BR112014013178A2 (pt) | 2017-06-13 |
WO2013083206A1 (en) | 2013-06-13 |
CA2858420A1 (en) | 2013-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103987708B (zh) | 4-羟基-1,2,3,4-四氢萘-1-基脲的衍生物及其在呼吸道疾病治疗中的用途 | |
CN103974953B (zh) | 激酶抑制剂 | |
JP6128449B2 (ja) | キナーゼ阻害剤 | |
EP2580212B1 (en) | Urea derivatives and their therapeutic use in the treatment of, inter alia, diseases of the respiratory tract | |
US9181242B2 (en) | Kinase inhibitors | |
US8883819B2 (en) | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension | |
US9359354B2 (en) | Kinase inhibitors | |
US9573949B2 (en) | Derivatives of [1, 2, 4] triazolo [4, 3-a] pyridine as P38—MAP kinase inhibitors | |
KR20110123741A (ko) | P38 mapk 억제제로서 유용한 피리미도피리다진 유도체 | |
US10364245B2 (en) | Kinase inhibitors | |
TW201730189A (zh) | 激酶抑制劑 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1199452 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1199452 Country of ref document: HK |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160622 Termination date: 20181209 |
|
CF01 | Termination of patent right due to non-payment of annual fee |